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I. PREFACE
Patents on upstream discoveries, if sufficiently broad in scope, impede
follow-on research and development, because access to the foundational
tools is blocked or restricted.
Congress possesses the power to "promote the Progress of ... useful
Arts by securing ... exclusive Right[s] to ... Discoveries."' The question
is whether granting patents to the discoverers of deoxyribose nucleic acid
(DNA) sequence fragments is useful. The U.S. Supreme Court, the Court
of Appeals for the Federal Circuit (CAFC), and the U.S. Patent and
Trademark Office (PTO) have set a precedent that patents on DNA or
genes are proper subject matter, novel, and nonobvious; thus, utility is the
only remaining standard left to test the validity of an application for a
DNA or gene patent.2 Though typically a lenient and slight barrier to
patentability, the utility requirement has gained significant importance in
biotechnology and chemistry. The utility doctrine is "a timing device,
helping to identify when an invention is ripe for patent protection,"
concerning itself with "patenting 'too close to the laboratory bench."' 4
To sum up the controversy addressed in this Article, the following
analogy from a critic of the current system highlights the ease with which
applicants have obtained patents related to gene sequence fragments:
Entities that claim patents on a gene with a particular utility is akin
to a company that tries to patent the word "the." The company
claims to have isolated the word by taking it out of the sentence that
usually surrounds it. The company has discovered that it can give
a description of the word "the" - it has three letters in a specific
order, etc. In this way, the company has also proven it is a new and
novel invention because "the" does not occur naturally in language
without at least a noun. The company says its researchers have
isolated and copied the word. As well, with its computers, the
1. U.S. CONST. art. I, § 8, cl. 8 (emphasis added).
2. In re Deuel, 51 F.3d 1552, 1559-60 (Fed. Cir. 1995) (DNA sequences encoding human
and bovine protein were not invalid as obvious where prior art only disclosed partial amino acid
sequence); In re Bell, 991 F.2d 781, 784 (Fed. Cir. 1993); Amgen v. Chugai Pharm. Co., 927 F.2d
1200, 1209 (Fed. Cir. 199 1) (holding that a unique probing and screening method employed by the
inventor in isolating the human erythropoietin (EPO) gene was not obvious).
3.

FEDERAL TRADE COMM'N, To PROMOTE INNOVATION: THE PROPER BALANCE OF

COMPETrION AND PATENT LAW POLICY, ch. 4, at 33 (Oct. 1993).
4. Id. at 34. The utility requirement's use relates to concerns that patents on basic research,
very far upstream, may impede follow-on innovation by virtue of effects on inventive and on access
to upstream technology. Id. Allowing too early patenting will create an "anticommons," where
inadequately or insufficiently developed follow-on technology is separately owned by too many
upstream owners. Id.
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company claims to have discovered that the word "the" occurs in,
say, 5% of sentences that are "soothing." The company says it has
found a correlation between "the" and soothing sentences. In its
patent application, therefore, the company claims that the "utility"
of the word "the" is that it has a correlation to soothing sentences.
This company hopes to produce products from the word "the,"
perhaps a whole series of sentences that are soothing.'
Though this analogy may seem far-fetched, since the word "the" has only
three letters, it should be noted the genetic code is composed of three-letter
words, known as "codons." 6 Like the word "the," every single living
organisms' genetic code uses "words" that are three letters long. In
simplistic terms, this Article contemplates the appropriateness of patenting
the word "the."
II. INTRODUCTION

A. Scope ofArticle
Because DNA sequences are genetic "information," should that not
distinguish them from other chemical compounds in the context of a patent
system?7 This wide-ranging question continues to be hotly debated by
5.

MATTHEW ALBRIGHT, PROFITS PENDING: How LIFE PATENTS REPRESENT THE BIGGEST

SWINDLE OF THE 21 ST CENTURY 123-124 (2004).
6. DNA is made up of nucleic bases composed of nucleotides (molecules) that each have
three components: (1) a sugar, (2) a phosphate, and (3) a base. See LARRY GONICK & MARK
WHEELIS, THE CARTOON GUIDE TO GENETICS 120 (1st ed. 1991). The bases are adenine, guanine,
cytosine and thymine. Id. Scientists decided to identify the bases with letters A, G, C, and T,
respectively. Id. Their "letters" (as a part of a nucleic acid base) make up DNA. See id. at 120-22.
From your DNA, the messenger RNA (mRNA) takes a "message" out from the nucleus (where
your chromosomes/DNA (DNA makes up your chromosomes) reside) into the cytoplasm (the area
in the cell surrounding the nucleus of the cell) where the ribosomes work with the transcription or
transfer RNA (tRNA). Id. at 133-34. The mRNA is also made up ofnucleotides like DNA with one
difference: its letters are A, G, C, and U. GONICK & WHEELIS, supra, at 132. The U substitutes for
the T. Id.Regardless, the ribosomes' and tRNAs' jobs are to read the mRNA's message, which the
mRNA copied from the DNA, to turn the message into amino acids that become proteins and
enzymes. Id. at 136-37. Each three letter "codon" is a code for a specific amino acid. Id. at 136.
7. NUFFIELD COUNCIL ON BIOETHICS, THE ETHICS ON PATENTING DNA: A DISCUSSION

PAPER, ExEcUIvE SUMMARY xi (July 2002); cf Hitzman v. Rutter, 243 F.3d 1345, 1349 n. I (Fed.
Cir. 2001) ("DNA is deoxyribonucleic acid, a generic term encompassing the many chemical
materials...."); Burroughs Wellcome Co. v. Barr Labs., Inc., 40 F.3d 1223, 1229 (Fed. Cir. 1994)
("DNA encoding a human protein [is
a] chemical compound."); Amgen, 927 F.2d at 1206 ("A gene
is a chemical compound ...").
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individuals in every walk of life.' There is a distinct lack of agreement,
even among the Justices of the U.S. Supreme Court, the CAFC, and the
Board of Patent Appeals and Interferences (BPAI). Though several cases
have held that DNA sequences are mere chemicals, 9 more recent cases
have addressed the distinction between the written description and
enablement requirements for patentability. The courts in those cases have
found sufficient differences between chemical compositions and genetic
material to conclude that, in genetic material cases, there is more basis for
a separate written description requirement than in a chemical composition
case.' Nevertheless, because of the breadth of this question, which many
believe requires a profound and deliberate examination of fundamental
aspects of life, this Article only examines the following: (1) whether
fragments of "a copy of DNA" (cDNA) sequences can and should be
patented under current policy and law; and (2) what the legal
consequences and implications may be for continuing research and
development and public health in the biotechnology field, if the PTO and
courts continue to allow patents on cDNA sequence fragments.
B. Confusion Causedby Loose Terminology in a New Field
It must also be noted at the outset that, because of the relative newness
of the sequencing of the human genetic code, terminology is used quite
loosely. The terms DNA sequences, cDNA, gene fragments, DNA
fragments, DNA or gene fragment sequences, and cDNA fragments
generally mean the same thing: a copy of a fragment of DNA containing
the code for a portion of a gene. Therefore, to correctly quote or reference
other cases, articles, and papers, this Article will, likewise, use these same
terms interchangeably, citing no difference in their definitions.

8. Public Comments on the United States Patent and Trademark Office "Revised Interim
Guidelines for Examination of Patent Applications Under the 35 U.S.C. § 112, 1 'Written
Description' Requirement," 64 Fed. Reg. 71427 (Dec. 21, 1999), available at http://www.uspto.
gov/web/offices/com/sol/comments/utilitywd/index.html (last visited Mar. 30, 2005); Public
Comments on the United States Patent and Trademark Office "Revised Interim Utility Examination
Guidelines," 64 Fed. Reg. 71440 (Dec. 21, 1999), corrected 65 Fed. Reg. 3425 (Jan. 21, 2000)
[hereinafter Revised Interim Utility Examination Guidelines] (in response to comments
complaining of broad patents that might issue on DNA sequences, the PTO states that "patents for
genes are treated the same as for other chemicals .. "), available at http://www.uspto.gov/web/
offices/com/sol/comments/utilguide/indexhtml (last visited Mar. 30, 2005).
9. Hitzman, 243 F.3d at 1349 n.l; Burroughs, 40 F.3d at 1229; Amgen, 927 F.2d at 1206.
10. Univ. of Rochester v. G.D. Searle & Co., 358 F.3d 916, 925 (Fed. Cir. 2004) ("[Iln fact,
where there might be some basis for finding a written description requirement to be satisfied in a
genetics case based on the complementariness of a nucleic acid and, for example, a protein, that
correspondence may be less clear in a non-genetic situation.").
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Loose use of the terminology is sometimes harmless and easily
corrected. Yet, in other situations, it can be problematic. This is easily
illustrated in a recent case where a court had to define terms used by the
parties. In Monsanto Co. v. Good, the district court had to assume and
define what one of the parties meant when referring to a "DNA construct."
The district court defined it as "DNA sequences, in light of the context.""
However, in a situation where loose use of terminology was not as
easily corrected, a former director for the PTO, the Honorable Todd Q.
Dickinson, testified before Congress, "[r]aw DNA sequenced data, such
as that recently generated by the Human Genome Project and various
corporate endeavors, is not patentable."' 2 However, the "raw DNA
sequenced data" generated by the Human Genome Project was cloned
DNA, not "raw data," unless Dickinson meant something else.' 3 Since the
CAFC had, at that time, concluded a gene was a mere chemical compound
and patentable, Dickinson must have meant otherwise. 4 Dickinson
meaning something different is also demonstrated through reports
revealing that, at the time of Dickinson's statement, up to six thousand
DNA fragment sequence patents had already been granted. 5 Surely then,
this statement must have been merely a result of a lack of universal
agreement on terminology. Indeed, Dickinson himself stated that

11. Monsanto Co. v. Good, No. Civ. A. 01-5678 FLW, 2004 WL 1664013, at *4 n.3 (D.N.J.
July 23, 2004).
12. On Gene Patents and Other Genomic Inventions: Oversight Hearing Before the
Subcomm. on Courts and Intellectual Property,House Comm. on the Judiciary, 106th Cong. 26
(D.C. 2000) [hereinafter Dickinson Statement] (statement of Honorable Todd Dickinson, Under
Secretary of Commerce for Intellectual Property and Director of the U.S. Patent and Trademark
Office, Dept. of Commerce), available at http://commdocs.house.gov/committees/judiciary/
hju66043.000/hju66043_0.htm (last visited Mar. 30, 2005).
13. The Human Genome Project sought to unveil the human genetic code in two stages: (1)
DNA from each chromosome was studied and organized; and then (2) the chromosomes (from
which the DNA is derived) were broken up into pieces that were then recovered as DNA clones.
THE GENOM1C REVOLUTION, UNVEILING THE UNITY OF LIFE 37 (Michael Yudell & Robert DeSalle
eds. 2002).
14. Amgen, 927 F.2d at 1206 ("A gene is a chemical compound, albeit a complex one, and
it is well established in our law that conception of a chemical compound requires that the inventor
be able to define it so as to distinguish it from other materials, and to describe how to obtain it.");
UtilityExaminationGuidelines, 66 Fed. Reg. 1092, 1093 (2001); Andrew T. Kight, Note, Pregnant
with Ambiguity: Credibilityand the PTO Utility Guidelinesin Light ofBrenner, 73 IND. L.J. 997,
1003 (1998).
15. Tanya Wei, Comment, Patenting Genomic Technology - 2001 Utility Examination
Guidelines:An Incomplete Remedy in Need of PromptReform, 44 SANTA CLARA L. REV. 307, 310
(2003).
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misinformation is the fuel behind the debates surrounding patents on genes
and genetic inventions. 6
Nevertheless, despite the confusion on terminology, the most important
fact is that human genes, as produced and used in the human body, are
viewed as different from the "genes, DNA, nucleotide sequences, nucleic
acids, etc.," currently being patented, because patents are allowed only on
genetic substances in their isolated and purified state, which requires
"human intervention."' 7 The U.S. Supreme Court has held that raw
products of nature, such as human DNA in its natural state, are not
patentable.' It is this difference that allows a patent to issue and defines
the limits of the patent. 9 "Gene" patents do not grant "inventors" property
rights of genes in other people's bodies.2° Nevertheless, this limit on
patenting raw products of nature has not resolved the escalating
controversies caused by continuing patenting of DNA sequence fragments.
C. The Beginning of the "Gene " Patent Controversy
Indeed, this controversy began when J.D. Watson and F.H.C. Crick
submitted an article to Nature magazine on April 25, 1953. Watson and
Crick "suggested a structure for the salt of deoxyribose nucleic acid
(D.N.A.).," 2 1 More intriguing, however, was their announcement containing

a suggestion that triggered an unexpected chain of events more quickly
than anticipated. Watson and Crick noted: "It has not escaped our notice
that the specific pairing we have postulated immediately suggests a
possible copying mechanism for the genetic material.,22 Though Watson

16. Dickinson Statement, supra note 12; see also Amgen v. Chugai Pharm. Co., 13
U.S.P.Q.2d 1737, 1759 (D. Mass. 1989) ("The invention claimed in the '008 patent is not.., the
DNA sequence encoding human EPO... [r]ather, the invention.., is the 'purified and isolated'
DNA sequence encoding erythropoietin."), aff'd in part, rev d in part, Amgen, 927 F.2d at 1209
(involving U.S. Patent No. 4,703,008, entitled "DNA Sequences Encoding Erythropoietin").
17. ROBERT P. MERGES& JOHN F. DUFFY, PATENT LAW AND POLICY: CASES AND MATERIALS
104 (3d ed. 2002).
18. Diamond v. Chakrabarty, 447 U.S. 303,309 (1980) ("[A] new mineral discovered in the
earth or a new plant found in the wild is not patentable subject matter."); Funk Bros. Seed Co. v.
Kalo Inoculant Co., 333 U.S. 127, 130 (1948) ("The qualities of these [unpatentablel bacteria [are]
like the heat of the sun, electricity, or the qualities of metals, [and they] are part of the storehouse
of knowledge of all men. They are manifestations of laws of nature, free to all men and reserved
exclusively to none.").
19. MERGES & DUFFY, supra note 17, at 104.
20. Id. (citing Utility Examination Guidelines, supra note 14).
21. J.D. Watson & F.H.C. Crick, Molecular Structure of Nucleic Acids, 4356 NATURE 737,
737 (1953).
22. Id. (emphasis added).
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was a proponent of interpreting the sequence of DNA, he did not appear
to support the patenting of DNA sequences.23
III. DEFINITION OF TERMS
Nonetheless, before delving much further, some genetic terminology
requires explanation. Though genome, genes, and their elements are
admittedly best understood after a course on genetics, alongside a view
through a high-resolution cooled CCD camera connected to a Zeiss
Axioplan 2 epifluorescence microscopesome, a few basic definitions are
necessary.
A. Genome
A genome is a collection of all genes in a cell. It is defined as the
"[t]otal genetic information carried by a cell or organism."24 The smallest
genome for a free-living organism (a bacterium) contains 600,000 DNA
base pairs." The human25genome has 3 billion DNA base pairs.21
The DNA in the human genome is arranged into 23 distinct
chromosomes, and each of these chromosomes is a physically separate
molecule that ranges in length from about 50 million to 250 million DNA
base pairs. 27 Each chromosome contains many genes, which are the basic
physical and functional units of heredity. 2 What is surprising, however,
is that genes comprise only about 2% of the human genome; the remainder
consists of non-coding regions whose functions may include providing
chromosomal structural integrity and regulating where, when, and how
many proteins are made. 29 The human genome is estimated to contain
20,000 to 25,000 genes.30
23. Kight, supra note 14, at 1004 (quoting Watson in context of the National Institute of
Health seeking patents on Dr. Craig Venter's automated cDNA sequences: "'[V]irtually any
monkey' can run an automated sequencing machine, and to allow patents on such sequences is
'pure lunacy."').
24. HARVEY LODISH ET AL., MOLECULAR CELL BIoLOGY, Glossary (W.H. Freeman ed., 4th
ed. 2000), availableat http://www.ncbi.nlm.nih. gov/books/bv.fcgi?rid=mcb.glossdiv.7880#7519
(last visited Mar. 30,2005).
25. Genomics and Its Impact on Science and Society: 2003 Primer:Early Insightsfrom the
Human DNA Sequence, Oak Ridge Nat'l Lab (The Human Genome Project and Beyond, Oakridge,
TN), 2003 [hereinafter Genomics], available at http://www.oml.gov/sci/techresources/Human_
Genome/publicat/primer200l/primerl 1.pdf (last visited Mar. 30, 2005).
26. Id.
27. Id.
28. Id.
29. Id.
30. Genomics, supra note 25.

2005]

SHOULD CONGRESS DO SOMETHING ABOUT UPSTREAM CLOGGING

In a multicellular organism, every cell has a copy of the same genome,
but not all cells express the same genes.3 It is for this reason that we are
all different. What expressed means, in the context of genes, is explained
below.
B. Gene
A gene is a subsection of a chromosome that encodes a specific
protein.32 It is an entity of a genome consisting of sequences that define the
gene product, and additional sequences directing its expression. Genes are
specific sequences of bases (nucleotide bases make up DNA) that encode
instructions about how to make proteins.33 In general terms, a gene is a
physical and functional unit of heredity that carries information from one
generation to the next.34 In more specific, or molecular, terms, it is the
36
35
entire DNA sequence, including exons, introns (a.k.a. "junk DNA"),
and non-coding transcription-control regions necessary for production of
a functional protein or RNA.37 The genetic code is the set of rules by

which nucleotide triplets in DNA or ribonucleic acid (RNA) specify amino
acids in proteins.3"
31. Id.
32. Michael D. Kane, Ph.D., Introduction to Computational Life Sciences 4 (1997)
(unpublished presentation, on file with Purdue Univ.), available at http://www.tech.purdue.edu/Cpt/
Courses/tech581V-Kane/lecturelintro.ppt (last visited Mar. 30, 2005).
33. Genomics, supra note 25.
34. LODISH ET AL., supra note 24.
35. An exon is "a region ofa gene that is present in the final functional transcript (mRNA)
from that gene." It is also "any non-intron section of the coding sequence ofa gene." Together "the
exons constitute the mRNA and are translated into protein." Mark Lefers, MA, Glossary Definition
of Exon, maintained by Holgrem Lab, available at http://www.biochem.northwestern.edu/
holmgren/Glossary/Definitions/Def-E/exon.html (last visited Mar. 30, 2005).
36. An intron is a meaningless sequence that is in the middle of a gene that can be several
hundreds ofnucleotides long, and is sometimes lovingly referred to as "junk." GONICK& WHEELIS,
supra note 6, at 148; see also Gane Ka-Shu Wong et al., Is "Junk" DNA Mostly Intron DNA?, 10
GENOME RES. 1672-78 (2000), available at www.genome.org/cgi/doi/l 0.1101/gr. 148900 (last
visited Mar. 30, 2005); Carole Nottenburg, Ph.D., J.D., Analysis of "JunkDNA "Patents, available
at http://lorac.typepad.com/patentblog/files/simons_patents-analysisf.pdf (last visited Mar. 30,
2005). The phrase "junk DNA" is attributed to Dr. Susumu Ohno, a very highly-regarded researcher
at the City of Hope in Duarte, California. See T.R. Gregory, The C-Value Enigma ch. I
(unpublished Ph.D. thesis, University of'Guelph, Ontario, Canada), availableat www.genomesize.
com/rgregory/thesis/ (last visited Mar. 30, 2005). In 1972, in an attempt to explain the paradox that
there was much more coding capacity in genomes than the number of genes, Ohno proposed that
much of the genome of more advanced eukaryotes was functionless. Id. He called this DNA
"garbage" or "junk" DNA. Id.
37. LODISH ET AL., supra note 24.

38. Id.
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C. DNA (including RNA, cDNA, mRNA, tRNA)
Two different kinds of genetic material exist: DNA and RNA.3 9 Most
organisms' genetic code is made of DNA, but a few viruses have RNA as
their genetic material.4" The biological information contained in an
organism is encoded in its DNA or RNA sequence. 4 '
1. The Material Composition of DNA
The three-dimensional structure ofDNA, first proposed by Watson and
Crick about fifty years ago, consists of two long helical strands that are
coiled around a common axis forming a double helix. 42 Each strand of
DNA is composed of just four different types of monomers,43 called
nucleotides. 44 Nucleotides are the building blocks for nucleic acids.45 An
individual nucleotide has three components: a sugar, a phosphate, and a
base. 46 At a molecular level, the sugar, phosphate, and base are hooked
together to make a long sugar-phosphate "backbone," with a sequence of
"bases" sticking off of the "backbone. 47 The bases are composed of
adenine, cytosine, guanine, and thymine (uracil, instead of thymine, in
RNA).48
As a result, a DNA molecule consists of two long polynucleotide
chains that are composed of the four types of nucleotide subunits. 49 Each
of these chains is known as a DNA chain, or a DNA strand. Hydrogen
bonds between the base portions of the nucleotides hold the two chains
together.5 ' In the case of the nucleotides in DNA, the sugar, deoxyribose,
39. National Center for Biotechnology information, A Science Primer- Just the Facts:A
Basic Introductionto the Science UnderlyingNCBI Resources, What is a Cell? [hereinafter What
is a Cell?],availableat http://www.ncbi.nlm.nih.gov/About/primer/geneticscell.html (last visited
Apr. 15, 2005).
40. Id.
41. Id.
42. LODISHETAL., supra note 24, § 1.2.
43. A monomer is any small molecule that can be linked with others of the same type to form
a polymer. Id.Examples include amino acids, nucleotides, and monosaccharides. Id. A polymer is
any large molecule composed of multiple identical or similar units (monomers) linked by covalent
bonds. Id.
44. Id.
45. GONICK & WHEELIS, supra note 6, at 106.

46. Id.
47. Id.
48. BRUCE ALBERTS ET AL., MOLECULAR BIOLOGY OF THE CELL, pt. II,
§ 4 (4th ed. 2002),
available at http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=mboc4 (last visited Mar. 30, 2005).
49. Id.
50. Id.
51. Id.
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is attached to a single phosphate group (hence the name deoxyribonucleic
acid), and the base may be either adenine (A), cytosine (C), guanine (G),
or thymine (7).52 Because only the base differs in each of the four types of
subunits, each polynucleotide chain in DNA is analogous to a necklace
(the backbone) strung with four types of beads (the four bases A, C, G, and
T)." These same symbols (A, C, G, and ) are also commonly used to
denote the four different nucleotides (that is, the bases with their attached
sugar and phosphate groups). 4 These symbols, ascribed by scientists,
created the alphabet of the genetic code.
2. The Principle of Complementarity
One very important characteristic of DNA that has made its sequencing
possible is the "principle of complementarity."55 Before Watson and Crick,
scientist Erwin Chargraff found that in any DNA, the number of As was
the same as the number of Ts; and the number of Cs was equal to the
number of Gs.56 In cracking this code, Watson and Crick realized each
base (A, G, C, or I) can only pair with one other base, called its
complement. Only G and C can pair, and likewise, only A and Tcan pair.57
This is due to the composition of the molecules and their "attraction,"
which is created by the atoms that have a negative or positive charge."
3. The Self-Replication of DNA
Gene-copying, or DNA replication, occurs when each strand (or chain)
of the DNA double helix, which contains the information necessary to
make its complementary strand, pulls apart. 9 In the neighborhood of the
"pulling-apart process," there are plenty of free nucleotides, which are the
building blocks for the new strand.6" Of course, because of the principle of
complementarity, what comprises the new strand is dictated by the strand
that just pulled apart.6' When a free nucleotide meets its complementary
base on the DNA, it sticks because its hydrogen bonding creates a weak
attraction between a hydrogen atom on one nucleotide molecule, and a
52. Id.
53. ALBERTS ET AL., supra note 48.

54.
55.
56.
57.
58.
59.
60.
61.

Id.
GONICK & WHEELIS, supra note 6, at 124.
Id. at 121.
Id. at 122.
Id.
Id. at 125.
GONICK & WHEELIS, supra note 6, at 126.
Id. at 125.
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non-hydrogen atom on the other molecule.62 If the wrong nucleotide comes
along, it will bounce away because of the required hydrogen bond.63
The principle of complementarity is the key to DNA's replication and
its code, which programs for creation of enzymes and proteins.' In fact,
the sequence of DNA parallels or reflects the sequence necessary to build
a protein.65 The sequence of the base pairs can be thought of as a series of
"words" specifying the order of amino acids in each protein.66 Through a
complex process, the "words" of the DNA are translated into instructions
specifying particular amino acids.67
4. The Role of RNA and DNA in Creating Proteins
RNA comes into the picture when the DNA words are translated into
amino acids. RNA is also a sugar-phosphate backbone with a series of
bases. 6' RNA is made up of four bases, but instead of A, C, G, and T, the
69
T is substituted by uracil (U), so RNA is composed of A, C, G, and U.
Protein synthesis begins when a region of DNA splits apart, just as in
DNA replication, except that a molecule of RNA, instead of a
complementary strand of DNA, is built along one strand.7° Just as in DNA
replication, each base of the RNA is complementary to the corresponding
DNA base, but instead of A and T matching up, it is A and U. This RNA
is called messenger RNA (mRNA) because it carries the genetic message
from the DNA to the protein factory.7 Since cells use proteins (enzymes)
to make other molecules like sugars or fats, DNA indirectly leads the
synthesis of many small molecules as well as proteins.72 DNA also
contains a coded set of instructions that
dictates when various proteins
73
must be made, and in what quantities.
The replication occurs in the nucleus of the cell. To do its job, however,
the mRNA gets its "code," or instructions, from the DNA by "copying" it,
and then moving from the nucleus of the cell to the cellular cytoplasm
62. Id. at 127.
63. Id.
64. Id. at 128.
65. GONICK & WHEELIS, supra note 6, at 130.

66.
67.
68.
69.
70.
71.
72.
73.

Id.
Id. at 131.
Id. at 132.
Id.
GONICK & WHEELIS, supra note 6, at 133.
Id. at 132-33.
LODISH ET AL., supranote 24, § 1.2.
Id.

SHOULD CONGRESS DO SOMETHING ABOUT UPSTREAM CLOGGING

outside the nucleus, where it serves as the template for protein synthesis.7 4
The mRNA is translated, through the help of tRNA (t stands for
transcription) and ribosomes, into a string of amino acids that will
constitute the protein molecule for which it codes.75
5. The Role of RNA's Replication of DNA in Creating DNA Copies
The genetic code is obtained by using mRNA, since mRNA is
essentially a copy of the coding regions of DNA.76 In the laboratory, the
mRNA molecule can be isolated and used as a template to synthesize a
cDNA strand.77 The cDNA refers to the other strand in a double helix and
often describes the cDNA strand to mRNA. Many mRNAs are published
as cDNA. The cDNA is made to solve the problem of mRNA being very
unstable outside of a cell.7" Scientists use special enzymes called reverse
transcriptase to convert the mRNA into cDNA.7 9 This process is called
"reverse" because using the cDNA is the reverse of the usual process of
transcriptions in cells.8" The usual process involves the mRNA "reading"
the DNA sequence as the template, but the reverse process involves
scientists using the mRNA as the template.8' Because mRNA is a reverse
copy of DNA, the cDNA represents only the "expressed," or coding
regions, of the DNA sequence. 2
D. Expressed Sequence Tags
Expressed Sequence Tags (ESTs) are partial sequences ofcDNA clones
corresponding to mRNA. 3 They are small copied pieces of DNA and are
74. Denise Casey, A Primer on Molecular Genetics 6, DOE Human Genome 1991-92
Program Report, availableat http://www.genome.iastate.edu/edu/doe/priml.html# 1 (last visited
Mar. 30, 2005).
75. See id. at 7-8.
76. See id. at 8.
77. Id.
78. National Center for Biotechnology Information, A Science Primer- Just the Facts:A
Basic Introductionto the Science UnderlyingNCB1Resources, ESTs: Gene Discovery Made Easier
[hereinafter ESTs], available at http://www.ncbi.nlm.nih.gov/About/primer/est.html (last visited
Mar. 30, 2005).
79. See generally What is a Cell?, supra note 39.
80. See D. Benjamin Borson, The Human Genome Projects: PatentingHuman Genes &
Biotechnology is the Human Genome Patentable?35 IDEA 461, 465-67 (1995).
81. See ESTs, supra note 78.
82. See id.
83. Press Release, HUGO Statement on the Patenting of DNA Sequences (Jan. 1995)
[hereinafter HUGO Statement], available at http://www.gene.ucl.ac.uk./hugo/patent.htm (last
visited Feb. 21, 2005). HUGO is the Human Genome Organisation, an international membership
organization whose goal is to coordinate and enhance efforts in genome research. Id.
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considered mere research tools.84 They are usually 200 to 500 nucleotides
long, 85 and are generated by sequencing either one or both ends of an
expressed gene.86 An EST can be used to identify an expressed gene and
can also be used as a sequence-tagged site marker to locate a particular
gene on a physical map of a genome.87 ESTs are called "tags" because they
are "sequenced" (i.e., the order, or sequence, of the deoxyribonucleic
acids, AGTCTTAGA, has been determined) bits of DNA that represent
genes expressed in certain cells, tissues, or organs.88 These "tags" are then
used to fish a gene out of a portion of chromosomal DNA by matching
base pairs."
According to many commentators, a "mere wisp of a gene sequence
from brain tissue, with almost nothing known about its function ... "
should not be a patentable product.90 Knowing the whole genome, will not
lead directly to cures for cancer and other killers. 9' The whole genome can
lead to new drugs, but it, much less an EST, cannot cure anything.92
Among the issues that have emerged during discussions of the members
of Human Genome Organisation (HUGO), a nongovernmental agency that
coordinates genetic research among countries,9 3 are the nature and extent
of scientific work involved in:
(1) the generation of ESTs;
(2) the use of ESTs to obtain full-length cDNA and gene sequences;
(3) the use of ESTs or full-length sequences to obtain expression of
proteins;
(4) the use of ESTs or full-length gene sequences to determine their
normal biological functions, association to disease(s) and their
RNA and protein products; and
(5) the use of genes or gene fragments for categorizing; mapping;
tissue typing; individual or forensic identification; production of
antibodies; antisense, triple helix and ribozyme applications; or
locating gene regions associated with genetic disease, etc.94

84.
85.
86.
87.
88.
89.
90.
91.
92.
93.
94.

ESTs, supra note 78.
Id.
Id.
HUGO Statement, supra note 83.
ESTs, supra note 78.
Id.
JANEs SHREEvE, THE GENOME WAR 84 (2004).

Id. at 16.
Id.
HUGO Statement, supra note 83.
Id.
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The concern generated by EST or DNA sequence fragment patents has
even led companies to sue companies in other countries and even the
countries themselves.9" But understanding how the genetic code is being
patented is necessary to fully understand the legal and policy issues
created.
IV. How GENE (DNA) FRAGMENTS

(A.K.A.

ESTs) ARE

BEING PATENTED

Every person's DNA is approximately 99.9% identical. 96 Therefore, it
does not matter "whose" DNA is selected.97 In fact, the publicly funded
Human Genome Project (HGS) created a BAC9' library made from a series
of anonymous individuals.99
Nonetheless, in a non-exhaustive list, the Nuffield Council on
Bioethics, has explained that genes or DNA sequences can, and do, appear
in patent claims in the following ways:
" the DNA sequence, whether comprising a complete or partial
gene;
* promoters;
" enhancers;
" individual exons;
" expressed sequences as expressed sequence tags (ESTs) or
cDNAs;
• whole transcribed genes as cDNAs;
• individual mutations known to cause disease;
" variations between people not associated with disease
(polymorphisms);
" cloning vectors, formed from bacterial DNA, which are used to
replicate DNA sequences;
" expression vectors, also formed from bacterial DNA, which are
used to express proteins in replicated DNA sequences;
• isolated host cells transformed with expression vectors, which
are cells that have been created to express particular proteins;
95. Infra Part IX.
96. THiE GENOMIC REVOLUTION, supra note 13, at 39.
97. Id.at 39-40.
98. At a very simplified level, a BAC is the resulting cloned DNA that was created by
inserting small pieces of DNA into bacteria that then replicated this portion of a chromosome
through division of itself. Id. at 39-40; see also GONICK & WHEELIS, supra note 6, at 185-86.
Therefore, a BAC library is based on replication through bacteria. Id.
99. THE GENOMIC REVOLUTION, supra note 13, at 40.
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*
*
*
*

amino acid sequences (proteins);
the use of such proteins as medicines;
antibodies, which are used as markers;
nucleic acid probes, which are fragments of DNA that are used
to locate particular parts of DNA sequences;
* methods of identifying the existence of a DNA sequence or a
mutation or deletion in an individual;
* testing kits for detecting genetic mutations; and
* whole genomes.' °
Many of these listed items contain DNA sequence fragments, and the
PTO has issued a few patents for gene fragments. 1" To get these
fragments, the traditional method used reverse transcription of mRNA to
make cDNA (a.k.a. cloning). The steps for making cDNA are the
following:
1. Create bacteria that transcribes the mRNA that codes for the
protein of interest.
a. Extract mRNA from cells that are making the protein of
interest.
b. Use reverse transcriptase to create a "library" of cDNA
molecules from the mRNA.
c. Insert these cDNA molecules into viral "vectors."
d. Infect bacteria in culture with the vectors containing the
desired cDNA.
2. Synthesize cDNA "probes" that can recognize the cDNA that
codes for the protein of interest.
a. Identify, isolate and purify the protein of interest.
b. Determine some of the exact sequence of the protein.
c. Predict codons which can code for the protein.
d. Manufacture DNA "probes" complementary to codons
predicted for the protein. This set may require making many
different probes to account for the redundancy in the genetic
code.
3. Identify colonies of bacteria whose DNA "hybridizes" to the
probe. These colonies contain cDNA that codes for the protein
of interest. Grow large amounts of, or "clone," this specific
bacterium, and finally isolate and purify the cDNA.

100. NUFFIELD COUNcIL ON BIOETHICS, supra note 7, at 25.
101. Wei, supra note 15.
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4. Remove the cDNA from the bacterial vector and insert it into a
vector suitable for expression in mammalian cells."0 2
Though cloning was the main method for identifying gene DNA
sequences, computational techniques have evolved, and they have now
become the main method. °3 These techniques rely on libraries like HGS's
BAC library, and they have sped up the sequencing process.
V. How THE NEWNESS AND COMPLEXITIES OF GENETICS MAY HAVE
LED TO THE PROBLEMATIC "PATENTABILITY" OF

EST PATENTS

Because computational techniques have sped up the process and
volume of sequences being discovered, the number of patent applications
being filed on whole gene sequences and DNA fragment sequences has
increased, and may be one of the reasons the PTO has granted patents on
ESTs. In addition, the complexities inherent in this area of science and
technology are also likely to blame for the PTO granting patents on DNA
fragments.
A. The Problem of the Sheer Volume and Cost of Examining DNA
Multi-Sequence Patents
With regard to the sheer volume of patents being filed, in a press
release dated October 23, 1996, the Honorable Bruce Lehman, a former
Commissioner of the PTO declared that:
the costs for determining even the initial patentability of the some
350 pending multi-sequence gene applications are prohibitive.
[The] PTO estimates that if one patent examiner were to tackle this
task, it would take approximately 200 years. To initially examine
these applications, the entire biotechnology group of some 200
examiners would take over one full year at a cost of over $34
million.'"

102. "Rarely does a single cDNA contain the entire sequence needed for protein expression.
Usually, many different pieces of cDNA, each of which codes for apart of the protein must be
linked together to create the 'full-length' sequence, which can be used to express the full-length
protein." Borson, supra note 80, at 465-66 n.9.
103. NUFFIELD COUNCIL ON BIOETHICS, supra note 7, at 25
104. PTO Press Release, PTO Announces New Policy to Process Gene-Sequence
Biotechnology Patents (Oct. 23, 1996), available at http://www.uspto.gov/web/offices/com/
speeches/96-2 I.txt (last visited Apr. 15, 2005).
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At the time of this press release in October of 1996, the number of
pending gene patent applications contained 500,000 isolated DNA and
RNA sequences of nucleotides.'0 5 This presented the PTO with "an
unprecedented search and examination challenge ...even with the most
modem equipment."'1 6 As a result, the PTO subsequently required
applicants for multi-sequence gene patents to claim no more than ten
independent and distinct nucleotide sequences for each application." 7
Furthermore, on top of the sheer volume, Lehman explained the PTO
simply did not have,
the resources to tackle this challenge under current policy. PTO
costs greatly exceed the $350,000 in application fees that we've
collected for these applications; we receive no taxpayer dollars and
simply cannot subsidize the applications of biotechnology
inventors. It's just not fair to the majority of our customer base,
inventors pursuing other worthwhile advances in different
technologies.'0 8
Since approximately 2000, the filing of applications for DNA/RNAbased patents has overwhelmed the PTO. In 1990, the PTO received
16,000 patent applications.' 0 9 In 2000, the number of patents had more
than doubled to 33,000.1"° According to the National Research Council, in
2001, the approximate number of patents issued by the PTO on DNA/RNA
fragments was 1400.1"' In 2002, the number of patents was between 13001350, and in 2003, the approximate number was between 1200-1300.112 In
2003, the two largest filers of these types of patent applications were
Incyte Pharmaceuticals, Inc. (Incyte) and HGS.'1 3 The high point for
DNA/RNA fragment patents occurred in approximately 1999, when the
USPTO granted Incyte nearly 100 patents
on DNA/RNA fragments, and
4
between 20 and 30 patents to HGS."
The exact number of patents that are currently issued on ESTs or gene
fragments is difficult to ascertain, however, because of the lag between
105.
106.
107.
108.
109.
110.

Id.
Id.
Id.
Id.
Wei, supra note 15, at 309.
Id

Ill. A PATENT SYSTEM FOR THE 21 ST CENTURY, NAT'L RESEARCH
ACADEMIES 56, 57 (Stephen A. Merrill et al. eds., 2004).
112. Id.
113. Id. at58.
114. Id.

COUNCIL OF THE NAT'L
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application filings and patent grants." 5 Nevertheless, in the context of
patents that contain any claims to DNA, the most current information
suggests that as of February 5, 2004, the PTO has granted 12,074 patents
to the 50 entities holding the largest number of DNA-based patents. 6 This
number accounts for only the 50 entities with the largest DNA-based
patent holdings. This number was generated from a search engine
containing a recently created, and apparently more effective, algorithm. In
fact, it may have been because of the problem of ascertaining the number
of DNA patents that are issued, that Dr. LeRoy Walters refined this new
search algorithm, allowing
the PTO to more effectively search DNA-based
7
issued."t
are
that
patents
B. The Problem of the Complexity of Examining DNA MultiSequence Patents
To provide readers a sense of the complexities involved in merely
searching the gene patents, the following is reported as the algorithm Dr.
Walters used and developed to search for DNA-based patents and their
total number:
((047???* OR 119* OR 260???* OR 426* OR 435* OR 514* OR
536022* OR 5360231 OR 536024* OR 536025* OR 800*) <in>
NC) AND ((antisense OR <case><wildcard>cDNA* OR
centromere OR deoxyoligonucleotide OR deoxyribonucleic OR
deoxyribonucleotide OR <case><wildcard>DNA* OR exon OR
"gene" OR "genes" OR genetic OR genome OR genomic OR
genotype OR haplotype OR intron OR <case><wildcard>mtDNA*
OR nucleic OR nucleotide OR oligonucleotide OR
oligodeoxynucleotide OR oligoribonucleotide OR plasmid OR
polymorphism OR polynucleotide OR polyribonucleotide OR
ribonucleotide OR ribonucleic OR "recombinant DNA" OR
<case><wildcard>RNA* OR <case><wildcard>mRNA* OR
<case><wildcard>rRNA* OR <case><wildcard>siRNA* OR
<case><wildcard>snRNA* OR <case><wildcard>tRNA* OR
115. Id. at 56.
116. LeRoy Walters, DNA PatentProject: DatabaseandSurvey, Kennedy Institute ofEthics
at Georgetown University (powerpoint presentation), at http://www7.nationalacademies.org/step/
Walters_ppt.ppt (last visited Mar. 30, 2005). Data is based on two research projects supported by
Grant No. R03 HG02683-02, "DNA Patent Policies at Academic Institutions," from the National
Human Genome Research Institute, NIH; and Grant No. DE FG 01 ER6317 1, "Enhancing the DNA
Patent Database," from the U.S. Department of Energy.
117. See Biographical Sketch of LeRoy Walters, PhD., available at http://philosophy.
georgetown.edu/faculty/bios/cvs/walters.pdf (last visited Mar. 30, 2005).
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ribonucleoprotein OR <case><wildcard>hnRNP* OR
<case><wildcard>snRNP* OR <case><wildcard>SNP*) <in>
CLAIMS)" '
What this algorithm means in plain English is:
Search US Patent classes 047 (plant husbandry), 119 (animal
husbandry), 260 (organic chemistry), 426 (food), 435 (molecular
biology and microbiology), 514 (drug, bio-affecting and body
treating compositions), 536/subclasses 22 through 23.1 (nucleic
acids, genes, etc., but not peptides or proteins), subclasses 24 and
25 (various nucleic acids, variants, and related methods), and class
800 (multicellular organisms).'
The algorithm further searches patents in a group that includes one or more
of the following terms in their claims: "antisense, cDNA, centromere,
deoxyoligonucleotide, deoxyribonucleic, deoxyribonucleotide, DNA (with
or without following letters, such as DNAs), exon, gene or genes (exact
match only), genetic, genome, genomic, genotype, haplotype, intron,
mtDNA (with or without following2°letters such as mtDNAs) - exact case
match only, nucleic, nucleotide."'
To further underscore the multifaceted difficulties faced by patent
examiners, the Honorable Todd Dickinson described to Congress the size
of some of the DNA-related patent applications being received in 2000.121
He testified that one patent application contained a DNA sequencing,
which if submitted on paper, would have totaled more than 400,000
pages. 2 2 Incredibly, however, more recent reports state that "one recent
biotech23patent application contained the equivalent of six million pages of
data."'

118. Waiters, supra note 116, at 4.
119. Id. at 5.
120. Id. at 6.
121. See generally Dickinson Statement, supra note 12.
122. Id.
123. Dashka Slater, HumouseTM, LEGAL AFF., Nov./Dec. 2002, at http://www.legalaffairs.
org/issues/November-December-2002/featureslaternovdec2002.html#top (last visited Mar. 30,
2005).
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VI. How THE

LAWS HAVE ALLOWED PATENTS ON DNA FRAGMENTS:
THE CONSTITUTION, THE STATUTES, TREATIES, AND AN ANALYSIS OF
PERTINENT CASES SINCE BRENNER V. MANSON

The next question that arises is how the law allows DNA fragment
patents to issue when an examination of the potential problems they raise
is, ironically, the very reason for which the law exists.
A. Statutory PatentingRequirements
The U.S. Constitution grants power to Congress to "promote the
Progress of... useful Arts by securing ...

exclusive Right[s] to ...

' In addition, in lay terms, to obtain a patent, the invention
Discoveries." 124
must meet the following requirements:

(1) it must be an invention or a discovery;
(2) that is a process, machine, manufacture, composition of matter or
improvement thereof;
(3) that is new, i.e., not already invented or discovered;
(4) that when compared to other inventions or discoveries in the same field
does not lead to the conclusion that the invention or discovery sought
to be patented would have been obvious to a person of ordinary skill in
that field (or the most closely related);
(5) that is useful; and
(6) for which a proper patent application has been filed with the PTO,
which means that a person of ordinary skill in the field of the invention
(or the most closely related) could read the application and understand:
(a) what it is through the full and precise description of the invention
in full, clear, concise, and exact words;
(b) how to make and use it through the full and precise description of
its makeup and use in full, clear, concise, and exact words; and
(c) which is the best way of making and using it. 25
B. Interpretationof the Laws by the Courts
the U.S. Supreme Court has taken a conservative view of
Historically,
26

"utility."

This conservative view is exemplified in Brenner, where the

Court denied an applicant's request to patent a process for making a

124. U.S. CONST. art. I, § 8, cl. 8 (emphasis added).
125. See 35 U.S.C. §§ 101-103 & 112.
126. See generally Brenner v. Manson, 383 U.S. 519 (1966).
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steroid and the steroid composition itself... However, depending on the
meaning of one of the last statements in the decision, one wonders if,
perhaps, it is possible the Court might now be amenable to allowing EST
patents.
In Brenner, the Patent Office denied the applicant's request for a
patent. Manson appealed to the Court of Customs and Patent Appeals
(CCPA), 128 which held the patent applicant, Manson, showed sufficient
utility for his claimed process because it "produce[d] a known product,
The
"...
[making] it [un]necessary to show utility for the product. . ,2'
Patent Office then sought a writ of certiorari, which the U.S. Supreme
Court granted in order to "resolve th[e] running dispute over what
constitute[d] 'utility' in chemical process claims."' 3 °
In its written opinion, the Court applauded the Patent Office for
"remain[ing] steadfast in its view" that a patent should not be granted upon
a product or process, if neither are useful.' 3 ' However, it did not treat the
CCPA as kindly, criticizing it for reversing the Patent Office's rejection
of a claim for a process that yielded mere chemical intermediates that were
only "useful to chemists doing research on steroids.'1 2 Noting the mood
of the Court, Manson took a reasonable position, and arguing that his
claimed process was useful enough to, at least, entitle him to an
interference proceeding under the Patent Office's utility standard because
a scientific article said an "adjacent homologue" of the steroid that his
process produced showed "tumor-inhibiting effects in mice."' 33 Manson
reasoned that this article disclosed sufficient utility, but despite this article,
the Patent Office rejected Manson's process because his application failed
to disclose "a sufficient likelihood" his steroid would have the same ability
to inhibit tumors as the "adjacent homologue."' 34 In addition, Manson
conceded that merely because the steroid yielded by his process was an
adjacent homologue to the one identified in the article, the field of steroids
was unpredictable.' 35 The Court, thus, reversed the CCPA's reversal of the
PTO's rejection, concluding, "Unless and until a process [and its product]
is refined and developed to [the] point where specific benefit exists in

127.
128.
129.
130.
131.
132.
133.
134.
135.

See id. at 522.
The CCPA is the predecessor to the CAFC.
Brenner, 383 U.S. at 522.
Id.
Id. at 530.
Id.
Id. at 531.
See generally Brenner, 383 U.S. at 531-32.
Id. at 532.
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currentlyavailableform - there is insufficientjustification for permitting
an applicant to monopolize what may prove to be a broad field."' 6
However, the Court concluded its opinion with a vague statement. The
Court stated it is not "blind to the prospect that what now seems without
'use' may tomorrow command the grateful attention of the public."'3 In
context of the first part of the sentence that preceded this statement, the
Court made clear it was not disparaging the importance of compounds and
processes like Manson's. Immediately following this ambiguous
statement, the Court made its famous "a patent is not a hunting license"
statement. 3 Therefore, it is unclear whether the Court was suggesting that
compounds and processes producing intermediates may one day be
patentable, or whether it was trying to make Manson feel better.
Regardless, though this statement is only dicta, the Court chose to print it
for some unknown reason.
Nonetheless, very soon thereafter, the CCPA confronted the
patentability of more steroid compounds in In re Joly.'39 Having been
castigated "on the record" only a year earlier by the Court, the CCPA
followed the Court's directives, expressly declaring it was "particularly
of the decision of the Supreme Court in
concerned with the applicability
140
Manson."'
v.
Brenner
Joly 14 1 involved a claim for "esters of 2-enols of steroids and
preparation thereof' that the applicants said would be useful as starting
materials to make "2, 3-keto compounds," which would be intermediates
for preparing other compounds. 42 However, neither the starting materials
nor the subsequently produced "intermediates" had any value, other than
to make compounds of unknown use. 43 The applicants contended that the
steroids produced by the "esters" in their process were "closely related,"
in chemical structure to other compounds of known usefulness, but they
presented no evidence that these "2,3-diketo steroids" possessed any
"propertiesor activities" in common with the alleged "closely related"
useful compounds. 44 The court rejected the argument that "disclosure of
a steroid as useful as an intermediate to make other steroids by specified
reactions [was] an adequate disclosure of utility.' 4 The CCPA affirmed
136.
137.
138.
139.
140.
141.
142.
143.
144.
145.

Id. at 534-35 (emphasis added).
Id. at 536.
Brenner, 383 U.S. at 536.
In re Joly, 376 F.2d 906, 907 (C.C.P.A. 1967).
Id.
Id.
Id. at 907.
Id. at 907-08.
Joly, 376 F.2d at 908.
Id.
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the PTO examiner's rejection on the basis of utility.'46 It also declared
there was no utility in a disclosure, claiming an intermediate existed that
worked, reacted, or could be used to produce an intended product of no
known use.'4 7 Furthermore, the CCPA pointed out it would also find
insufficient utility for a product obtained from intermediates belonging to
some class of48compounds that now is, or might in the future be, the subject
of research. 1
In a companion case, In re Kirk, the CCPA confronted additional
similar claims for steroid compounds the applicants claimed had valuable
"biological properties," value in "the furtherance of steroidal research,"
value as "intermediates in prepar[ing]" other steroids and "biologically
active compounds," and that could "be applied to veterinary or medical
practice in the form of tablets, elixirs, injections, implants or other
pharmaceutical preparations."' 49 Despite the fact that the applicants
submitted an affidavit showing "one skilled in the art [could] determine
biological uses," the examiner rejected the patent application because the
specification lacked disclosure of utility. 50 The BPAI agreed, pointing out
that "biological properties" of the claimed compounds was "so general and
vague as to be meaningless."''
The CCPA affirmed the rejection on the grounds that it seemed the
applicants made "nebulous expressions of 'biological activity' or
'biological properties,"' which were set out in their specification gave no
more indication of the usefulness of the compounds, or how to use them,
than did the equally obscure expressions of "useful for technical and
pharmaceutical purposes," unsuccessfully relied on by another applicant
in a prior case. 5 2 The CCPA treated the submitted affidavit as an irrelevant
"expostfacto affirmation" and characterized its content as merely showing
that a PHOSITA 53 would know how to use the compounds to figure out
whether the compounds are useful. 5 4 The CCPA also mentioned that even
if the specification had stated that the claimed compounds were similar to
other useful compounds, such a statement would have been incredible
since steroids are known to be unpredictable.'55
146.
147.
148.
149.
150.
151.
152.
153.
154.
155.

Id. at 909.
Id. at 908.
Id.
In re Kirk, 376 F.2d 936, 938 (C.C.P.A. 1967).
Id. at 940.
Id.
Id. at 941 (citing In re Diedrich, 318 F.2d 946 (C.C.P.A. 1963)).
PHOSITA stands for a "Person Having Ordinary Skill In The Art."
Kirk, 376 F.2d at 940.
See id. at 942.
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Furthermore, perhaps because of the vehement dissent or to bolster its
opinion, the Kirk majority declared that the In re Nelson'56 case relied on
by the applicant, which fully supported the applicants' position, was
overruled by Brenner.'" It also declared "a specification that disclosed a
steroid that was an intermediate that 'work[ed],' reacted, or could be used
to produce some product of no known use," would, nonetheless, fail the
utility requirement.158 As it declared in Joly, it was also not enough that the
product obtained from the intermediate belonged to some class of
compounds that now is, or might in the future be, the subject of research.'59
But in the next sentence, the CCPA did not overrule, and instead invited
the reader to compare, Reiners v. Mehltretter, where the CCPA held,
"[C]ompounds employed as intermediates to produce other directlyuseful
compounds were found to be themselves useful."' 6 A "compare"
introductory signal means the CCPA thought the holding in Reiners was
sufficiently analogous to lend support to its previous statement that the
disclosed product would not meet the utility requirement if the product
produced by the intermediate was not immediately useful.' 6 ' This implies
the CCPA would consider an application disclosing intermediates that
produced directly useful compounds as meeting the utility requirement.
Nonetheless, it took another thirteen years before the CCPA was again
confronted with the utility issue in the context of chemical compositions.
Perhaps because it was thirteen years later, and fourteen years since the
Brenner case, the CCPA decision appears to completely contradict its Kirk
and Joly decisions, while ignoring Brenner. However, In re Jolles'62 can
be reconciled.
Jolles filed a patent application for pharmaceutical compositions and
methods useful for the treatment of acute myeloblastic leukemia in human
patients. 63
1 The examiner rejected the claims on the grounds of"no utility,"
citing as her reason insufficient evidence of the compositions'
"operativeness" and safety and efficacy "to treat acute myeloblastic
leukemia in human patients."'" She said the claims were "incredible.' 65
156. Id. at 943 (citing In re Nelson, 280 F.2d 172 (C.C.P.A. 1960)).
157. Id. at 946.
158. Id. at 945.
159. Kirk, 376 F.2d at 945.
160. Id.(citing Reiners v. Mehltretter, 236 F.2d 418, 421 (C.C.P.A. 1956)).
161. Id. at 946 n.1 1; id. at 950 (citing Reiners v. Mehltretter, 236 F.2d 418, 421 (C.C.P.A.
1956)); THE BLUEBOOK: A UNIFORM SYSTEM OF CITATION R. 1.2(a), at 23 (Columbia Law Review
Ass'n et al. eds., 17th ed. 2000).
162. See In re Jolles, 628 F.2d 1322 (C.C.P.A. 1980).
163. Id. at 1322-23.
164. Id. at 1325.
165. See id.-at 1327.
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Furthermore, no methods of treatment or pharmaceutical compositions for
use in humans were set out in the specification, no dosages were described,
' 66
and how the invention was to be used was left "to speculation.'
However, as the losing applicant did in Kirk, the Jolles applicant filed
affidavits indicating one of eight compounds had "substantial activity
against experimental tumors in mice in tests customarily used for the
screening of anti-cancer agents of potential utility in the treatment of
humans," but the examiner rejected these references. 167 The timing of the
affidavits, however, is crucial to note: in Kirk, the affidavit was filed after
the final rejection, whereas in Jolles, the affidavits were filed "in" the
application. 6 Therefore, in reversing the examiner's and BPAI's decision,
the CAFC relied heavily on the Jolles affidavits to show that a PHOSITA
would find the claimed uses credible. 69 The CAFC concluded that
evidence of efficacy of the compound in laboratory animals, as shown in
the affidavits, was sufficient to show closely related compounds had the
requisite utility for treating humans. 7 ° In reaching this conclusion, the
CAFC also cited In re Buting 7 ' and In re Bergel,72 which support the
proposition that testing in animals or mice was relevant to the utility of the
components in humans.' 7 3 Furthermore, in reaching this conclusion, the
CAFC held the BPAI erred in dismissing evidence in one of the affidavits
that declared the testing in mice was routinely used to screen anticancer
agents of potential utility in humans.
In addition, in another "utility" case, Cross v. Iizuka,'74 involving a
priority contest, the CAFC rejected the argument that in vivo tests were
necessary to establish a practical utility. Instead they held that the
demonstration of the in vitro activity of a novel pharmaceutical agent was
enough to establish statutory utility. 75 More importantly, as in Jolles, the
Court pointed to expert testimony to uphold the examiner's and BPAI's
where the
disputed finding of utility.7 6 This seems to conflict with Kirk, 177
expert evidence was rejected as an "ex post facto affirmation."

166.
167.
168.
169.
170.
171.
172.
173.
174.
175.
176.
177.

Id.
Jolles, 628 F.2d at 1324.
In re Kirk, 376 F.2d 936, 939 (C.C.P.A. 1967); Jolles, 628 F.2d at 1323-24.
Jolles, 628 F.2d at 1327.
Id. at 1327-28.
In re Buting, 418 F.2d 540 (C.C.P.A. 1969).
In re Bergel, 292 F.2d 955 (C.C.P.A. 1961).
Jolles, 628 F.2d at 1327.
Cross v. lizuka, 753 F.2d 1040 (Fed. Cir. 1985).
Id. at 1051.
Id. at 1049.
See In re Kirk, 376 F.2d 936, 940 (C.C.P.A. 1967).
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A more careful reading of Cross, however, reveals that after the
examiner's final decision, the expert testimony was presented during a
priority contest, and the evidence presented through the testimony was the
"fact" that, in essence, the utility, though not as detailed as desired, was
nonetheless actually "there" because a PHOSITA would know the utility
at the time the application was filed.'78 According to the Court, the BPAI
found the application "disclosed some activity or utility. . . .," yet the
appellant argued this was insufficient to show practical utility.'79 In citing
that cases holding "[e]vidence of any utility is sufficient when the court
does not recite any particular utility," the Court agreed with the BPAI that
the application "disclosed that it was generally known in the art, as of the
critical date, that the parent ...compounds possessed" use; this was
further supported by the expert testimony. 8 The Court, likewise,
concluded that the same expert testimony also proved a PHOSITA would
know "how to use" the compound even though the application did not
specify how, because the PHOSITA had, on the critical date, "information
as to the approximate dosage levels... ."'"In addition, citing Brenner as
a source for "broad guidelines," the CAFC declared, "[T]here is a
reasonable correlation between the disclosed in vitro utility and an in vivo
activity, and therefore a rigorous correlation is not necessary where the
disclosure of pharmacological activity is reasonable based upon the
probative evidence."'8 2
In addition, in Amgen, Inc. v. ChugaiPharmaceuticalCo. ,83 which is
known more for its obviousness analysis, the Court briefly addressed
utility in the context of enablement. The Court invalidated broad claims
that were unsupported by a sufficient number of examples of use the Court
felt were needed to validate Amgen's broad claims. In recognizing the lack
of predictability in the art of isolating and using purified, isolated DNA
sequences encoding human Erythropoietin (EPO), the court declared that
"[f]or DNA sequences, [an applicant must disclose] how to make and use
enough sequences to justify grant of the claims sought."' 84 This result
occurred because, in deposition, the head of Amgen's EPO analog
program confessed they did not know whether the EPO analogs "had the
[useful] biological property of causing bone marrow cells to increase

178.
179.
180.
181.
182.
183.
184.

Cross, 753 F.2d at 1044-45.
Id.at 1045.
Id. at 1049.
Id. at 1051.
Id. at 1050.
Amgen v. Chugai Pharm. Co., 927 F.2d 1200, 1212-15 (Fed. Cir. 1991).
Id.at 1213.
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production . .. ""'. And in its specification, Amgen made extensive
statements concerning all of the EPO gene analogs that could be made, yet
disclosed how to make and use only a few." 6 Furthermore, the Court knew
and noted, "There may be many other genetic sequences that code for
EPO-type proteins."' 7 Therefore, because Amgen was trying to claim all
EPO analogs, but only disclosed how to make and use a few, the Court
invalidated Amgen's claims. 8 This suggests that, if an applicant fully
enables the applicant's invention or discovery, the Court will be less
stringent in applying section 103 utility. However, if the enablement is
weak, the Court will strictly demand complete and specific descriptions of
section 103 utility.
Nevertheless, in the most recent chemical composition case, In re
Brana, the CAFC ruled in favor of the applicant, reversing the PTO's
rejection of no utility of an antitumor agent.8 9 The PTO based its rejection
on the specification's failure to describe any specific disease against which
the claimed compounds were active, and the fact only in vitro tests had
been performed, requiring the applicant to cite to similar compounds
showing in vivo activity.' In disregarding a reference showing some
laboratory oncologists were skeptical about the predictive value of in vivo
models for human therapy, the CAFC declared human clinical testing was
not necessary to establish practical utility for an invention having
therapeutic utility.'' The CAFC also gave little weight to the fact that
changes in chemical compounds could radically alter the chemical's effect
on humans; at the time, it accepted prior art references that disclosed
structurally similar compounds proven, in vivo, to be effective anticancer
agents against various tumor models.' Seemingly contrary to Kirk and
Joly, the CAFC stated evidence of success in structurally similar
compounds was relevant in determining whether one skilled in the art
would believe an asserted utility. 93
Though many have interpreted Brana as conflicting with Brenner and
its progeny, the cases can be read as consistent with one another. Both
decisions set forth the standard for determining a specific utility: an
appropriate use of homologous art can provide credible support or a well185. Id.
186. Id.
187. Id.
188. Amgen, 927 F.2d at 1213.
189. In re Brana, 51 F.3d 1560 (Fed. Cir. 1995).
190. Id. at 1564 (the examiner cited § 112 as grounds for rejection, but § 101 would have also
been proper).
191. Id.at 1568.
192. Id.at 1567.
193. Id.
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established utility. Indeed, in Brana, the applicants relied on more than
mere evidence from structurally similar compounds.'94 The applicants
relied on in vivo and in vitro mouse model systems to test the antitumor
activities oftheir compounds.'95 The applicants also submitted an affidavit
containing evidence of the utility of the claimed compounds in vivo, even
though they only tested in vitro. 96 In fact, before making it to the CAFC,
the applicants already overcame the section 103 utility rejection. 97 They
were before the CAFC, on the examiner's final rejection based on the
specification failing to show "how-to-use" the compound under section
112. ' 98 However, relying again on the affidavit, the CAFC reversed the
section 112 rejection because prior art and the submitted affidavit showed
several compounds within the scope of the applicants' claims did exhibit
antitumor activity in vivo.' 99 This is unlike Mason's claims and evidence
in Brenner. In Brenner, where the Court reached an opposite result, the
context was highly unpredictable compounds, and Mason failed to provide
evidence to show his steroids possessed any of the same useful tumorinhibiting properties as the prior art homologues. Therefore, though
Brenner is not mentioned in Brana, perhaps it was not raised because of
the critical factual differences. These differences might have made the
cases so dissimilar that, if the CAFC had mentioned Brenner, its mention
could have been viewed as inapposite.
Summing up the meaning of these cases, in context of DNA sequence
fragments, can one predict how the Court or the CAFC would rule?
Though the Court in Brenner invalidated the patent claiming steroids, it
recognized "that what [in 1966] seems without 'use' may tomorrow
command the grateful attention of the public. ' '2 1 Could this be viewed as
the Court hinting it might, in the future, be amenable to loosening its strict
application of the utility requirement? At this time, it is unknown. Based
on its holdings, however, the Court has been historically opposed to
patents. Therefore, the odds are that it would maintain its strict
interpretation.
The CAFC and its predecessor, the CCPA, however, have been quite
liberal in upholding and enforcing patents in the pharmaceutical and
biotechnology fields.2° ' In fact, as long as the slightest evidence has been
194.
195.
196.
197.
198.
199.
200.
201.

Brana, 51 F.3d at 1563.
Id.
Id.
Id.
Id.
Brana, 51 F.3d at 1563, 1565-66.
Brenner, 383 U.S. at 536.
See ADAM B. JAFFE & JOSH LERNER, INNOVATION AND ITS DISCONTENTS: How OUR
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put forward to support a disclosure of utility, the CCPA has ruled in favor
of the applicant. 2 Only in those cases where the applicant was unable to
come forward with any relevant evidence of utility did the CCPA rule
against the applicant." 3 In addition, it has been the CAFC's position that
minimal utility is all that is required to obtain a patent.2°" The CAFC tends
to give expert and PHOSITA evidence great weight. 5 If any of this
evidence is credible, it seems to find in favor of the applicant, regardless
of the PTO's ruling.20 6 Though the CAFC has rejected gene-related
applications under the written description and enablement requirement, the
CAFC has intimated it might take a more lenient approach. It believes that,
by having only the amino acid sequence of a protein, one can be in
possession of the entire genus of DNA sequences that encode a disclosed
partial protein sequence, "even if individual species within that genus
might not have been rendered obvious. ' To meet the written description
requirement, the CAFC does not require a patent applicant to list every
possible permutation of nucleic acid sequences that can encode a particular
protein for which the amino acid sequence is disclosed.2 8 This approach
recognizes the degeneracy of the genetic code, but it also means once a
protein is claimed through a DNA or amino acid sequence, the applicant
obtains a monopoly on all nucleic acid sequences that code for the
particular protein. Since these sequences do not have to be expressly
identified in the patent application it is unclear how another person is
supposed to know what sequences have already been patented.
IT 9-11 (2004). The CAFC has "significantly broadened and strengthened the rights of patent
holders." Id. at 10. "Patents have become so easy to get, and are enforced so ruthlessly by the courts
that the winners of the technological competition in crucial industries are sometimes those with the
best lawyers, or those simply lucky enough to have been awarded a key patent they did not really
deserve, rather than those that have created the best products or services." Id. at 19.
202. See, e.g., Nelson v. Bowler, 626 F.2d 853 (C.C.P.A. 1980); In re Malachowski, 530 F.2d
1402 (C.C.P.A. 1976); In re Gaubert, 524 F.2d 1222 (C.C.P.A. 1975); In re Gazave, 379 F.2d 973
(C.C.P.A. 1967); In re Hartop, 311 F.2d 249 (C.C.P.A. 1962); In re Krimmel, 292 F.2d 948
(C.C.P.A. 1961).
203. See, e.g., In re Citron, 325 F.2d 254 (C.C.P.A. 1964) (uncharacterized biological extract
not supported with scientifically credible utility); In re Buting, 418 F.2d 540, 542 (C.C.P.A. 1969)
(credible basis not established for the claim that the single class of compounds has utility in treating
different kinds of cancers); In re Novak, 306 F.2d 924 (C.C.P.A. 1962) (grounds proffered for
utility of claimed compounds could not affect claimed physiological activity).
204. Brenner v. Manson, 383 U.S 519, 522 (1966); contra Envirotech Corp. v. Al George,
Inc., 730 F.2d 753, 762 (Fed. Cir. 1984) ("[Tlhe fact that an invention has only limited utility and
is only operable in certain applications is not grounds for finding lack of utility."); Brooktree Corp.
v. Advanced Micro Devices, Inc., 977 F.2d 1555 (Fed. Cir. 1992).
205. See supra text accompanying notes 161-98.
206. Id.
207. In re Wallach, 378 F.3d 1330, 1333 (Fed. Cir. 2004).
208. Id. at 1334.
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More recently, criticizing the CAFC, a publication decrying the
"broken patent system" has complained that "certain aspects of
biotechnology such as genetic sequences are all technologies for which the
courts have expanded the range of patentable subject-matter beyond what
was perceived to be patentable at the end of the 1970. " 029
As a result, if
utility is the only issue before the CAFC on a DNA fragment application,
it is likely the CAFC would rule in favor of the applicant.
C. Application of the Law by the PTO
The PTO has historically been more conservative. In Ex parte
Aggarwal," ° the BPAI found no utility for an antitumor pharmaceutical
agent on grounds that the applicant failed to disclose "evidence showing
substantial activity in screening tests customarily used and accepted as
predictive of human activity for the type of chemical tested." '' Though
the applicant's specification contained many broad statements regarding
utility, and it described administration of the chemical, lymphotoxin, via
virtually all known routes available for administering anticancer
substances, the actual illustrations and explanations of utility were
sparse." 2 The application was virtually devoid of teachings to support the
broad scope of its claims. 1 3 Additionally, even though the applicant
submitted an affidavit to support his claimed utility, as reported by the
BPAI, the affidavit seemed neutral to negative." 4 In addition, the BPAI
agreed with the examiner that there was "considerable doubt that those
skilled in the art would be willing to accept [the applicant's] in vitro tests

209.
210.
211.
212.
213.
214.

supra note 201, at 198.
23 U.S.P.Q.2d 1334 (Bd. Pat. App. & Interf. 1992).
Id. at 1339.
Id. at 1337-38.
Id. at 1338.
JAFFE & LERNER,

The declaration admits that it is not possible, particularly in the early stages of
development of a given candidate chemotherapeutic agent, "to predict in advance
whether a selected tumor is susceptible to treatment with the agent." The Sherwin
declaration does not state that lymphotoxins are useful against tumors or that
practitioners skilled in the art know how to use lymphotoxin. All that is said is that
(1) oncologists will "not be misled" by the assertion of broad anti-tumor activity,
(2) routine and conventional clinical studies will be conducted to "more fully
refine the activity of the agent," and (3) though "extensive and burdensome," the
studies involve nothing more than "routine manipulations."
Id. at 1339.
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and in vivo tests as established models predictive of utility against tumors
in humans."2 '
Additionally, though Aggarwal has been cited as conflicting with
Cross, it does not necessarily conflict, since the basis for the rejection in
Aggarwal was the breadth of the claims that were unsupported by the prior
art or the submitted affidavit.21 6 In addition, according to the BPAI, the
specification was "virtually devoid of teachings that indicate[d] the broad
scope of lymphotoxins claimed has the broad scope of utility asserted. 21 7
In the more recent case of Ex parte Fisher,1 8 the BPAI also took a
more conservative approach, rejecting an EST patent application that did
not meet the utility standards set out by the PTO.2" 9 In Fisher, which
involved plant ESTs, the examiner rejected an application on more than
32,236 ESTs, commenting that the uses specified by the applicants were
"non-specific uses that are applicable to nucleic acids in general and not
particular or specific to the nucleic acids being claimed., 22' The applicants
had stated the DNA sequences might be useful, essentially, as a probe.22 '
Though the BPAI upheld the examiner's rejection on utility and
enablement grounds (but reversed on the written description requirement),
it made a statement that suggests ESTs might have utility.222 The BPAI
said, even if it agreed that monitoring the expression of uncharacterized
223
nucleic acids would be useful, each sequence is not necessarily useful.
"A patentable utility divided by a thousand does not necessarily equal a
thousand patentable utilities., 224 However, the BPAI was in some ways
equivocal on whether it would ever allow a patent like the applicants'
215. Aggarwal, 23 U.S.P.Q.2d at 1338.
216. See id. at 1338 n.8 (distinguishing Cross v. lizuka, 753 F.2d 1040 (Fed. Cir. 1985)).
217. Id. at 1339.
218. 72 U.S.P.Q.2d 1020 (Bd. Pat. App.& Interf. 2004).
219. See Mary Ann Liebert,ESTs Failto Make the Grade,Again, 23 BIOmEcHNoLoGY L. REP.
571, 571-72 (2004).
220. Fisher,72 U.S.P.Q.2d at 1022; see also Liebert, supra note 219,at 571.
221. Liebert, supra note 219 at 571.
[The applicants] stated that their sequences might be useful for several purposes,
such as producing a plant that synthesized lower than normal amounts of a given
protein, determining an association between a genetic polymorphism and a
particular trait, isolating a particular genetic region, detecting mutations, as
molecular tags, and for identification of tissues.
Id.
222. See id. at 571-72.
223. Id. at 572.
224. Exparte Xuanchuan Yu, Appeal No.2004-1761, 2004 WL 2733632, at *12 (Bd. Pat.
App. & Interf.2004) (unpublished opinion).
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application, perhaps indicating its rulings will land somewhere in between
the loose utility guidelines of 1995 and the stricter utility guidelines of
2001.
In fact, the more recent utility guidelines, put in effect in January 2001,
are stricter than the utility guidelines of 1995, but a PTO examiner may
still grant a DNA fragment patent, since there is a lack of much needed
guidance. 25 Many maintain that the guidelines do not address the issuance
of DNA fragment patents.226 Nevertheless, according to Dickinson, the
asserted utility of a gene patent will be considered credible by patent
examiners "unless the logic underlying the assertion is seriously flawed,
or the facts upon which the assertion is based are inconsistent with the
logic underlying the assertion., 227 Because this statement is somewhat
murky, Dickinson provided an example: "at least some nucleic acids might
be used as probes, chromosome markers, or diagnostic markers. Therefore,
the per se credibility 22of
assertions regarding the use of nucleic acids is not
8
questioned.
usually
According to the 2001 Utility Guidelines,
[t]he patentee is required to disclose only one utility, that is, teach
others how to use the invention in at least one way. The patentee is
not required to disclose all possible uses, but promoting the
subsequent discovery of other uses is one of the benefits of the
patent system.229
In addition, the patent applications must show a well established utility
defined as specific, substantial and credible. 20 This means the patent
examiner must "determine if the assertion of utility is credible (i.e.,
whether the assertion of utility is believable to a person of ordinary skill
in the art based on the totality of evidence and reasoning provided). ' 231 To
determine credibility, the examiner must look to the reliability of the
patent applicant's assertion based on the logic and facts offered to support
225. See USPTO Revised Interim Utility Guidelines Training Materials, ex. 10, at 53-55
(1999) [hereinafter USPTO Revised Training Materials] (DNA Fragment encoding a Full Open
Reading Frame), available at http://www.uspto.gov/web/menu/utility.pdf (last visited Mar. 30,
2005).
226. See, e.g., Wei, supra note 15, at 311, 327.
227. Dickinson Statement, supra note 12, at 27.
228. Id.
229. Utility Examination Guidelines, supra note 14, at 1094.
230. USPTO Revised Training Materials, supra note 225, at 3; see also USPTO MANUAL OF
PATENT EXAMINING PROCEDURE § 2107.01 (ed. 8, rev. 1, Feb. 2003).
231. USPTO Revised Training Materials, supra note 225, at 5.
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the assertion of utility.23 2 Accordingly, an assertion of utility for nucleic
acids, claiming they could be used as probes, chromosome markers,
forensic markers, or diagnostic markers is credible, but such a use might
fail the specific and substantial utility tests.233
To be a specific utility means the utility asserted is specific to the
subject matter claimed, which is contrasted with a "general" utility that
would only apply to the invention's broad class.2 34 If a claimed
polynucleotide use is disclosed simply as a "gene probe" or "chromosome
marker," then it would not be considered a specific utility in the absence
of a disclosure of a specific DNA target. 235 Likewise, general statements
of diagnostic utility, such as diagnosing an unspecified disease, would be
insufficient unless a specific condition for diagnosis is disclosed.236
A "substantial utility" is a "real world" use, which means that if further
research must be performed to identify or reasonably confirm a "real
world" use, there is no substantial utility.2 37 A "well established utility" is
a specific, substantial, and credible utility that is well-known, immediately
apparent, or implied by the specification's disclosure of the properties of
a material, alone or taken with the knowledge of one skilled in the art23
It does not encompass a nonspecific utility that would apply to virtually
every member of a general class of materials, such as proteins or DNA.239
However, the CAFC seems to contradict the requirement for a well
established utility since it allows statements of nonspecific utility. By
having only the amino acid sequence of a protein, the CAFC says one can
be in possession of the entire genus of DNA sequences that encode a
disclosed partial protein sequence, "even if individual species within that
genus might not have been described or rendered obvious. ' ' 240 Though the
Guidelines disallow broad nonspecific utilities that would apply to every
member of a general class, the CAFC's statement implies that the
Guidelines are wrong, since if one is not required to identify all of the
sequences that encode for the protein, a statement of a specific utility for
each unidentified sequence need not be specified, and a broad statement
would suffice. As confusing as it is, the CAFC is lenient and may very
well disagree with the PTO's Guidelines. Despite the fact that, in fleshing
out the guidelines for both the utility and written description requirements,
232.
233.
234.
235.
236.
237.
238.
239.
240.

See id.
Id.
Id.
Id.
USPTO Revised Training Materials, supra note 225, at 5-6.
Id. at 6.
Id. at 7.
Id.
In re Wallach, 378 F.3d 1330, 1333 (Fed. Cir. 2004).
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the PTO has applied case law based on chemical fact issues, 241 the CAFC
may still reverse the PTO on an EST patent.
Furthermore, the PTO's use of chemical composition-based case law
results in questionable conclusions. The guidelines state that, if a patent
application claims a "nucleic acid" that bases its utility on "homology to
existing nucleic acids or proteins having an accepted utility, the asserted
utility must be accepted . . . unless . . . rebut[ted]. 242 Likewise, the
guidelines allow one protein's function to be imputed to another based on
homology. 243 These statements, however, contradict chemical practice, and
furthermore, risk the issuance of a patent on an EST displaying a high
degree of homology to other DNA fragment sequences that could actually
exert the opposite, or a very different, effect. 244 The utility of DNA
fragment patents is not always known. 245 This leaves broad gaps, and it has
likely predisposed the utility guideline training materials to errors in
application through the examples it provides.246
In conjunction with the Revised Interim Utility Guidelines Training
Materials, the PTO also issued the Synopsis of Application of Written
Description Guidelines. 247 These guidelines have limited relevance to the
utility inquiries because "the specification must teach those of skill in the
art 'how to make and how to use the invention as broadly as it is
claimed. ' 248 They also lack sufficient guidance, and in one of the more
controversial examples, the PTO rejects (for the wrong reasons) a claim
directed to "A DNA comprising the EST of SEQ ID NO: 1," stating
substitution of the word "gene" for "DNA" would solve the problem.249
The PTO says use of the term "gene" in the preamble of an EST claim

241. J. Timothy Meigs, Biotechnology Patent Prosecution in View of PTO's Utility
Examination Guidelines, 83 J.PAT. & TRADEMARK OFF. Soc'Y 451, 474 (2001).
242. Utility Examination Guidelines, supra note 14, at 1096.
243. Id.
244. See Natalie A. Lissy, Note, Patentabilityof Chemical and Biotechnology Inventions: A
Discrepancyin Standards, 81 WASH. U. L.Q. 1069, 1078 (2003).
245. See Wei, supra note 15, at 311.
246. See Revised Interim Utility Examination Guidelines, supra note 8, cmt. 44, at 81-89
(NIH, Jack Spiegel, Ph.D.); accord Joshua C. Benson, Note, Resuscitating the Patent Utility
Requirement, Again: A Return to Brenner v. Manson, 36 U.C. DAVIS L. REv. 267, 291 (2002)
(citing Timothy A. Worrall, Note, The 2001 PTO Utility ExaminationGuidelinesand DNA Patents,
16 BERKLEY TECH. L.J. 123, 133 (200 1)).
247. USPTO Synopsis of Application of Written Description Guidelines (1999), availableat
http://www.uspto.gov/web/menu/written.pdf (last visited Mar. 30, 2005).
248. In re Goodman, II F.3d 1046,1050 (Fed. Cir. 1993) (quoting In re Vaeck, 947 F.2d 488,
496 (Fed. Cir. 1991) (emphasis added)).
249. See.Stephen G. Kunin, Written DescriptionGuidelinesand Utility Guidelines,82 J. PAT.
& TRADEMARK OFF. SOC'Y 77, 91-92 (2000).
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may raise a written description issue because of the ambiguity of what an
accurate description of a "gene" really is.2" °
Nevertheless, it is still unclear what practical impact the guidelines
" ' Because of the lag between
have had on the examiners' behavior.25
application filings and patent grants, the PTO output is difficult to
measure."2 Additionally, to provide a full assessment of the effect of the
written description and utility guidelines on DNA patents would require
analysis of the scope of issued claims and the types of nucleic acids
claimed (full-length coding sequences, ESTs, and antisense fragments), in
addition to an analysis of the number of DNA sequence patent applications
the USPTO forced applicants to separate into individual sequences.253
Furthermore, the utility guidelines have not yet been interpreted or
applied by a court. On July 23, 2004, in Monsanto Co. v. Good, the
District Court for the District of New Jersey rejected one party's
interpretation of the utility guidelines. 254 However, the district court did
not interpret the guidelines; it merely quoted them. 5

250. See KENNETH J.BuRCHFmL, BIOTECHNOLOGY AND THE FEDERAL CIRcUIT 55 (Dale H.
Hoscheit & Lisa M. Hemmendinger eds., Cumm. Supp. 2000). This is supported, however, by the
fact that not all molecular biologists and geneticists agree that a "gene" really exists at all. See, e.g.,
EVELYN Fox KELLER, Is THERE AN ORGANISM IN THis TEXT?, in CONTROLLING OUR DESTINIES:
HISTORICAL, PHILOSOPHICAL, ETHICAL, AND THEOLOGICAL PERSPECTIVES ON THE HUMAN GENOME
PROJECT 273-76 (Phillip R. Sloan ed., 2000). The word "gene" was a term chosen by a scientist to
identify various interesting regions of nucleic acids or genomic text. See id. at 273-75. In fact, the
concept of "genes" has never been stable, "unitary, comprehensive, or 'clean."' Id. at 275.
Questions have arisen as to whether a gene really even tangibly exists, since a gene is the sequence
of nucleotides transcribed and translated into a polypeptide chain, and may not come into existence
until after the DNA has been read by the mRNA, and the mRNA has been spliced. See id. at 27576. As such, the "gene" does not really reside on the chromosome, and perhaps not even in the
nucleus. Id. at 276.
251. A PATENT SYSTEM FOR THE 21ST CENTURY, supra note 111, at 56.
252. Id.; accordALBRIGHT, supra note 5, at 2 n.5.
The number of life patents waiting and already awarded by the U.S.P.T.O. seems
to vary greatly depending on who is asked in the patent office.... [One source]
claimed that 20,000 patents on genes or gene-related molecules [had
issued] ....
One year earlier, the former director of the U.S.P.T.O. told a
Congressional subcommittee that there had been only 6,000 patents awarded....
Id.
253. A PATENT SYSTEM FOR THE 2!ST CENTURY, supra note I 1l, at 57-58.
254. See Monsanto Co. v. Good, No. Civ. A. 01-5678 FLW, 2004 WL 1664013, at *5 (D.N.J.
July 23, 2004).
255. See id.
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D. Relevant Treaties - TRIPs
Finally, in addition to the U.S. Constitution, the statutes, case law and
the PTO guidelines, there are standards set out in a treaty that specifically
addresses patents. In the last few years, the United States, along with
hundreds of other countries joined the World Trade Organization and
signed the Agreement Trade Related Aspects of Intellectual Property
(TRIPs). Therefore, the United States must now comply with its
provisions. The enforcement of TRIPs takes place through the World
Trade Organization, which authorizes the application of compelling
penalties to ensure compliance. The provisions applicable to the problem
of EST patents are TRIPs articles 8 and 27. Article 27 of TRIPs allows
patents to be granted for inventions that are "new, involve an inventive
256
' It also disallows any
step and are capable of industrial application."
member country to discriminate against patent rights due to field of
technology." 7 However, article 27(3) specifically excludes from the antidiscrimination provision a country's treatment of patents on "diagnostic,
therapeutic and surgical methods for the treatment of humans. 25 8
Presently, no cases construe the meaning of "field of technology." The
only complaint pending before the World Trade Organization regarding
discrimination on the basis of field of technology involves a complaint
made by Canada on December 7, 1998, alleging that a patent term
extension scheme was implemented under the European Community
regulation Nos. 1768/92 and 1610/96, and that this patent term extension
scheme was limited to pharmaceutical and agricultural chemical
products. 2 9 However, the pharmaceutical and agricultural chemical
products field is far broader than the discrete portion of DNA gene
fragments that are in the field of biotechnology. So, one could argue that
mere modification of laws regulating the granting of patent rights on DNA
sequence fragments is not a discrimination against an entire field of
technology. ESTs are a miniscule part of the field of genetics,
biotechnology, and biology. Therefore, modifying only the area affecting
DNA fragment sequence patents does not affect an entire field of
technology.
Furthermore, in context of the issue presented herein, the relevant
TRIPs provisions arguably conflict with each other. Although, if read in
256. Agreement on Trade-Related Aspects of Intellectual Property Rights, Apr. 15, 1994, 33
I.L.M. 92, art. 27(1) (emphasis added) [hereafter TRIPs Agreement].
257. Id
258. Id.art. 27(3)(a).
259. See Request for Consultations by Canada, European Communities- Patent Protection
for Pharmaceutical and Agricultural Products, WT/DS153/1, 1998 WL 842152 (W.T.O. Dec. 7,
1998).
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a vacuum, they do not appear to conflict, once applied to EST patents there
is a good argument they do conflict. Under article 27(1) of TRIPs, if the
U.S. grants patents on fragments of DNA, such patents would arguably
violate the provision requiring patents to be granted on inventions that "are
capable of industrial application. '260 It would seem that DNA sequence
fragments for which no well established (i.e., credible, substantial and
specific) utility can be adequately described, or fragments that are
identified as merely probes or research tools, cannot meet the TRIPs
requirement that patents be granted only on inventions capable of
industrial application. Therefore, arguably, to come into compliance with
TRIPs, Congress must change the law to prohibit granting patents on
ESTs. However, if Congress did modify the laws applying to EST patents,
TRIPs might be equally violated since modification of the current U.S.
discrimination
patent laws could violate the TRIPs provision disallowing
261
against patent rights in a "field of technology.
However, pursuant to article 27(3), countries are specifically allowed
to exclude from patents inventions involving "diagnostic [or] therapeutic
methods ... for the treatment of humans., 26 2 Moreover, article 8(1) of
TRIPs, which sets forth the general principles behind TRIPs, states that
members "may, in formulating or amending their laws and regulations,
adopt measures necessary to protect public health ...and to promote the
public interest in sectors of vital importance to their socio-economic and
technological development. ' 263 Clearly, many in the medical, genetics and
biotechnology fields, including other countries, have been troubled by the
PTO's allowance of DNA fragment sequence patents.2 This concern has
been raised because of the potential problem of the "anticommons. '"265
Therefore, though at first blush compliance with TRIPs can be a
concern, there are three provisions that could support changes in the law
with regard to ESTs: Article 8(1), 27(1)(a), and 27(3). As a result,
Congress could arguably modify the law governing issuance of DNA
fragment patents without violating TRIPs.

260. TRIPs Agreement, supra note 256, art. 27(1).
261. Id.
262. Id. art. 27(3)(a).
263. Id.art. 8(l).
264. See infra Part VIII.
265. See generally Michael A. Heller & Rebecca S. Eisenberg, CanPatentsDeter Innovation?
The Anticommons in Biomedical Research, 280 SCIENCE 698 (1998).
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VII. WHY EST PATENTS HAVE CAUSED PUBLIC OUTCRY
Though the utility and written description guidelines are helpful, they
are not stringent enough to prevent the granting of patents on ESTs, DNA
sequence fragments, for which there is no real known utility, or objects on
which the most valuable utility, among many other unknown utilities, has
yet to be determined.26 6 Furthermore, it seems the CAFC and the PTO have
decided to gloss over the real issues of whether gene fragment patents are
proper subject matter, novel, nonobvious, and useful.267 By focusing on the
technicalities of claim drafting, the attention has been removed from the
subject matter and utility requirement and has made them "toothless. 268
This has compelled many nongovernmental organizations to publicize
their opinions. The Nuffield Council on Bioethics points to a common
criticism of DNA sequence patenting: the sequences only carry
information telling the body how to construct and produce proteins, and
therefore cannot be patented, but can only be discovered as a product of
nature.269 Another main concern about granting patent rights over DNA
sequences is that in a composition of matter patent, the patent owner has
exclusive rights over all subsequent uses of that sequence.27 °
Though significant amounts of information about identification of one
DNA sequence can be obtained from a partial DNA sequence (one can
infer the presumed protein function between a DNA sequence that is
similar to a previously characterized and identified gene, known as a fulllength DNA sequence), the process of getting from an identified EST to
a full-length cDNA or gene sequence is not simple. 27 ' A "full-length"
cDNA is an
image of the entire sequence of the mRNA it copies or
"mirrors., 272 However, according to HUGO, using these partial DNA
sequences to find full-length cDNA is an important research activity, even
though it is not always successfully accomplished.2 73 To properly and
successfully obtain a full-length cDNA or gene sequence requires the
development of methods, strategies, and techniques to deal with the many
266. See generally Wei, supra note 15.
267. See John M. Conley & Roberte Makowski, Back to the Future: Rethinking the Product
of Nature Doctrineas a Barrierto Biotechnology Patents(Part ), 85 J. PAT. & TRADEMARK OFF.

Soc'Y 301, 301-06 (2003).
268. See id. at 304-05 (quoting John M. Golden, Biotechnology, Technology Policy, and
Patentability:NaturalProductsand Invention in the American System, 50 EMORY L.J. 112, 127
(2001).
269. See NUFFIELD COUNCIL ON BIOETHICS, supra note 7, at 27.
270. Id. at 53.
271. HUGO Statement, supra note 83.
272. Id.
273. Id.
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issues and problems that occur in the process, and such efforts may take
from a matter of weeks (when extremely short, or easily cloned genes are
involved), to more than a year.274 In addition, it may also be necessary to
screen multiple cDNA libraries and tissue sources, or to use a variety of
cloning-based and polymerase chain reaction-based techniques. 2"
Furthermore, in addition to the difficulties faced in obtaining a useful
DNA fragment or sequence, there are further obstacles that can complicate
the generation of this fragment into a useful product that correctly
expresses a gene.276 Successful cloning of this fragment to produce the
correct expression construction does not always occur easily because
finding the right host to correctly reproduce the DNA fragment's
expression creates many other problems. 2"
As a result, not only is the review and examination of gene fragment
patents a difficult, complex, expensive, and time-consuming task for the
PTO, it is also controversial because with new technologies, the effort
required to isolate and characterize an EST is small compared to the work
of isolating and characterizing a gene and gene product, finding out what
it does, and developing a commercial product.27 Furthermore, because a
gene can be expressed as mRNA many times, ESTs ultimately derived
from mRNA may be redundant.7 9 "Redundant" means there may be many
identical or similar copies of the same EST.28° This redundancy and
overlap means a person searching for a particular EST in a computer

274. Id.
275. Id.
276. HUGO Statement, supra note 83.
277.
For instance, it may be necessary to attempt cloning in multiple hosts, including
bacterial, yeast, insect, and mammalian cells, to find a usable host. There is no
guarantee as to what expression vector and gene structure will be adequate for the
task. Moreover, there is little way to know in advance what cell types will produce
the appropriate post-translational modifications. Each expression construction
must also allow for appropriate promoters, high affinity translation sequences, and
often enhancers and splice junctions.
Id.
278. Genetics and Patenting,Human Genome Project Information, Genome Management
Information System of the Dept. of Energy, Office of Biological and Environmental Research
(formerly Office of Health and Environmental Research) Genome Programs Task Group, at
http://www.oml.gov/sci/techresources/HumanGenome/elsilpatents.shtml#2 (last visited Feb. 21,
2005).
279. See What is a Cell?, supra note 39.
280. See id.
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may retrieve a long list of tags, many of which represent the same
database
281
gene.
Therefore, those who do attempt to, and sometimes successfully, obtain
gene fragment patents are said to own "gatekeeper" patents allowing them
to exercise undue control over the commercial fruits of genome
research.282 Though only recently occurring, this will likely result in
multiple patents on different parts of the same genome sequence, adding
undue costs to a researcher who wants to examine the sequence. 23 This is
because multiple patents may have issued on a gene fragment, the gene,
and the protein.2" As a result, if a researcher wants to examine the
sequence, she will have to pay each patent holder a fee for the opportunity
to study the sequence.28 5 Of course, she would first have to pay someone
to research the patents to determine which ones apply to the sequence she
wants to study, and then hope that the patent holders would be willing to
allow her to examine the sequence for a fee. 2 6 If she is lucky, she will
locate all of the patents, be allowed to pay a reasonable license fee, and not
miss a patent that she would infringe and for which she would likely be
sued.
VIII. WHY CONGRESS HAS THE POWER TO Do SOMETHING ABOUT

EST PATENTS

As a result of the above, Congress must do something to protect the
public health of this country. The problem probably has its origin in the
PTO's application of the law Congress created. With only one or two
exceptions, the PTO treats all patent applications the same way: "From
gear shifts to genomics, [the PTO] applies the same norms to all inventions
and technologies. .

.

. Just as the patent system has nurtured the

development of telephony, aeronautics, and computers, so, too, will it
281. See id.

282. See Genetics and Patenting, supra note 278. In the context of bioengineered and
genetically engineered food, ActionAid, which is a charitable organization active in more than
thirty countries, is one of a number of organizations calling for a complete rethink of the provisions
of the TRIPs Agreement that apply to the patenting of life forms. JoffWild, The Future for Patents
on Life, Jan. 2000, available athttp://thomsonscientific.com/ipmatters/patlifej8l800O6 (last visited
Feb. 21, 2005). Alex Wijeratna, the international food rights campaign coordinator in the UK
branch ofActionAid, claims "there should be no patents on staple crops. Food security in the south
needs to be ring fenced, it is too important to leave to intellectual property and the private sector."
Id.
283. Genetics and Patenting, supra note 278.
284. Id.
285. Id.

286. Id.
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ensure that the new discoveries
in genomics lead to healthier, longer lives
28 7
for all of humankind.,

However, because "Congress is free to amend § 101 so as to exclude
from patent protection organisms produced by genetic engineering, ' ' 28 it
is, likewise, free to amend section 101 to impose regulations, conditions
or more stringent requirements on the issuance of DNA sequence
fragments. "Or it may choose to craft a statute specifically designed for
such .

.

. things."28 9 In fact, Congress has once before taken action on

genetic research by imposing conditions under which such research could
be performed.29° It has also continued to do so indirectly, by charging the
NIH with the task of publishing
its Guidelines for Research Involving
291
Recombinant DNA Molecules.
IX. WHY THE QUESTIONABLE "UTILITY" OF ESTs IS IMPORTANT
ENOUGH TO ASK CONGRESS TO IMPLEMENT CHANGES

Because the functions are unknown for more than 50% of discovered
genes, 292 it reasonably follows that their utility cannot be identified, and
the patenting of ESTs, with even less known functions, must be restricted.
Furthermore, because the human genome sequence is almost (99.9%)
identical in all humans,2 93 allowing patents on DNA fragment sequences
has caused, and will likely continue to cause overlapping, therefore
blocking patent rights. 4 Only about 2% of the genome encodes
instructions, and genes appear to be concentrated in random areas along
the genome, with vast expanses of non-coding DNA in between.295
On pending applications, the utility of gene fragments has been
identified by vague terms, like providing "scientific probes" to help find
a gene or another EST, or to help map a chromosome.296 Questions have
287. Dickinson Statement, supra note 12, at 18, 21.
288. Diamond v. Chakrabarty, 447 U.S. 303, 318 (1980).
289. Id.
290. See id. at 317 n.I I (citing 41 Fed. Reg. 27902 (1976)).
291. See Notices, Department of Human Health and Services, 66 Fed. Reg. 57970 (Nov. 19,
2001). In these guidelines, the NIH was, inter alia,resolving how to balance the need for disclosure
of information to the public about gene transfer research with the desire to keep trade secret
information confidential. See id.
292. Genomics, supra note 25.
293. Id.
294. See Donald L. Zuhn, Jr., DNA Patentability: Shutting the Door to the Utility
Requirement, 34 J.MARSHALL L. REV. 973, 994 (2001).
295. Genomics, supra note 25.
296. Genetics and Patenting,supra note 278.
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arisen over the issue of when, from discovery to development into useful
products, exclusive right to genes can, if ever, be claimed.297
A. The Grantingof EST Patents Rewards the Wrong Entity
Initially the method for identifying and cloning a gene cost between
$40,000 and $50,000, and required a researcher to work backwards from
a known biological function.298 After identifying a known biological
function, the researcher would isolate and purify the responsible proteins,
and then use degenerate DNA probes to locate the corresponding gene.29 9
This was not only expensive, but also time consuming.
Subsequently, though highly criticized, Dr. Craig Venter found a way
to resolve the time and money issue of sequencing DNA. His approach
was so modem that most had never heard of it: it was driven by
reductionism. 00 His strategy of discovery was based on the belief that, the
more he divided natural phenomena into its constituent parts, and those
parts into subparts and so forth, the more he could learn how nature really
works.30 ' But because it was too simplified, many were stunned to hear
that Venter sought patents on DNA fragments sequenced by his automated
machine.30 2 When James Watson3 3 heard Venter was seeking patents on
the'EST sequences, he was stunned. He said that allowing patents on these
cDNA sequences was "pure lunacy," and further commented that
"virtually any monkey" could run the automated sequencing machines. 3
Indeed, Venter relied on the many cDNA libraries that had been
constructed since the mid-1970s from many sources, including different
organisms, tissues, and functional cellular states.0 5 The idea of coupling
297. Id.
298. Kight, supra note 14, at 1003.
299. Id.
300. SHREEVE, supra note 90, at 7.
301. Id.
302. Venter, developed an improved approach by using cDNA sequencing to identify genes.
See Kight, supranote 14, at 1003. Venter used an automated sequencer that, instead of identifying
a full-length gene or DNA sequence, identified an edited copy of a gene that contained only the
protein-coding regions. Id. This edited gene, known as cDNA, is much shorter, and can be
characterized more quickly. Id. Venter identified and copied only the mRNA molecules into
sturdier strands of what he termed cDNA, and this cDNA would then be processed in the
sequencing machine. Id. Venter's process of identifying cDNA cost only approximately twenty
dollars a piece. Id. Venter sought patent protection for these sequences while working at NIH.
Kight, supra note 14, at 1003.
303. Watson and Crick identified the double helix structure of DNA. See supra Part II.C.
304. Kight, supra note 14, at 1004 (citing Leslie Roberts, Genome PatentFight Erupts, 254
SCIENCE 184, 184 (1991) (quoting James Watson).
305. See HUGO Statement, supra note 83.
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DNA sequencing to cDNAs was discussed as early as 1986.306
Nevertheless, many issues and problems still plague the use of ESTs to
obtain full-length cDNA and gene sequences.30 7 In addition, HUGO does
not agree with the patenting of partial and uncharacterized cDNA
sequences because it believes those grants will reward those who make
routine discoveries, but penalize those who determine biological function
or application. 30 ' Allowing patents on DNA fragments will impede the
development of diagnostics and therapeutics.30 9 Partial and uncharacterized
cDNA sequences (ESTs) constitute research tools that should not be
patented.310
B. The Grantingof EST Patents Has Blocked the Disseminationof
Knowledge Creatingthe "Anticommons"
One of the purposes of the patent system is "to encourage
dissemination of information concerning discoveries and inventions."3 1'
The government wants to encourage inventors of new processes to
publicize the event for the benefit of the entire scientific community, thus
widening the search for uses and increasing the fund of scientific
knowledge. 1 2 Unfortunately, it appears the contrary is occurring in the
case of gene fragments.
The granting of a patent that has not been sufficiently developed so as
to disclose a specific utility creates a "monopoly of knowledge which
should be granted only if clearly commanded by the statute.3 a3 Such a
306. Id.
307. See id.
[Ilt remains a task that is fraught with uncertainty. In some cases known
techniques such as specific primer extensions may be successful; in others
extraordinary skill will be required to overcome obstacles such as secondary
structure. Foreseeable obstacles include the difficulty or impossibility of cloning
mRNAs that are large or that encode poorly clonable sequences; the problems
posed by immature, or incorrectly or alternatively spliced messages; the
difficulties posed by cross-hybridization among members of gene families; and the
rare but extremely challenging problems posed by post-transcriptional alternations
of RNA sequence.
Id.
308. Id.
309. Id.
310. See HUGO Statement, supra note 83; NUFFIELD COUNCIL ON BIOETHICS, supra note 7,

at 81-82.
311. Brenner v. Manson, 383 U.S. 519, 533 (1966).
312. Id.
313. Id. at 534.
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monopoly without being useful may, nonetheless, "engross a vast,
unknown, and perhaps unknowable area."3 4 It appears patents that have
issued on DNA sequence fragments have obtained a monopoly on a
grossly vast and unknown area.
The Nuffield Council on Bioethics reports three concerns with the
patenting of DNA arguing human DNA sequence patents should not be
allowed because: (1) human DNA sequences have a special status; (2) the
patent applications do not meet the legal criteria for patenting; and (3)
there are possible negative effects on health care and research related to
health care. 31" To support the argument that genes have an inalienable
nature, it cites a European Community Directive.316
In addition, according to the National Research Council during
deliberations for creation of the report, "A Patent System for the 21st
Century," the realm of biotechnology research and development, as
primarily applied to human health, was repeatedly raised as an area where
' 3 17
there might be "a significant problem of access to patented technology.
Patents on upstream discoveries, if sufficiently broad in scope, can impede
follow-on research and development if access to the foundation in
intellectual property is restricted. I Indeed, "[p]atents of dubious quality
only invite legal challenges that divert money and other resources from
more productive purposes . . . such • •as ,,319raising venture capital,
commercializing inventions and creating jobs.
Currently, because the PTO has already awarded patents on 162 human
genes to HGS, and the PTO has applications pending on 7,500 more,32 °
there is little left to patent. The top gene-patent holders, Incyte, Celera
Genomics, Hyseq (now known as Nuvelo, Inc.), Millennium
Pharmaceuticals, and HGS, own nearly 1,000 life patents, and have
314. Id.
315. NUFFmLD CouNCIL ON BIOETHICS, supra note 7, at 21.
316. See id. at 22; Council Directive 98/44/EC, 1998 O.J. (L 213) 13, available at http://
europa.eu.int/scadplus/leg/en/vb/126026.htm (last visited May 5, 2005) "The human body, at the
various stages of its formation and development, and the simple discovery of one of its elements,
including the sequence or partial sequence of a gene, cannot constitute patentable inventions."
Council Directive 98/44/EC, art. 5(1). However, the EC does differentiate between copies of DNA
through section two, which states: "An element isolated from the human body or otherwise
produced by means of a technical process, including the sequence or partial sequence of a gene,
may constitute a patentable invention, even if the structure of that element is identical to that of a
natural element." Id., art. 5(2).
317. A PATENT SYSTEM FOR THE 21 ST CENTURY, supra note 11, at 71.
318. Id.
319. PatentQualityImprovement: HearingBefore the Subcomm. on Courts,the Internet,and
Intellectual Property, of the House Comm. on the Judiciary, 108th Cong. 2 (2003) (opening
statement by Rep. Smith, Chair, Subcomm. On Courts, the Internet and Intellectual Property).
320. ALBRIGHT, supra note 5, at 29.
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applied for 25,000 more.32' Considering these companies are all
biopharmaceutical companies that base their pharmaceuticals on genetics,
and that there are only about 32,000 genes, one must wonder if there will
be any "upstream territory" left in the public domain.322
Allowing DNA sequencing patents means research on genetic testing
has been inhibited.3 23 Almost half of the research laboratories in the United
States surveyed have ceased to pursue some research because of existing
patents.324 The patenting of research tools has already occurred, and the
result is that researchers now need to pay royalties on multiple distinct
research tools in order to market a given product, thereby retarding the
inventive process.325
The World Health Organization has begun to investigate how to deal
with the blockage of information flow and data access, and it is evaluating
whether an "open genomics" might be a viable option.3 26 In 1997, 34% of
the 2,167 life science (not just genetic) researchers surveyed by Dr. David
Blumenthal, of Massachusetts General Hospital, reported they had been
denied access to research results from other institutions.327 More troubling,
however, is that in 2002, a survey found that 47% of university geneticists
were denied access to other scientists' research results.328 Many geneticists
have delayed release of their own research results by more than 6 months
in the past 3 years giving as their main reason, "the need to wait for a
patent application. ,329 Contrast this with one biologist's comment, "At one
time, if you found something exciting, you would run down the corridor

321. Id. Albright uses the term "life patents" which include patents on human genes, deadly
diseases, whole animal species, plants, seed and foodstuffs (genetic makeup of rice and corn). Each
of these companies' main products are based on gene patents. For more information, see Incyte
Corporation Web Site, at http://www.incyte.com/ (last visited Mar. 30, 2005); Celera Genomics
Web Site, at http://www.celera.com/celera/about (last visited Mar. 30, 2005); HGS Web Site, at
http://www.hgsi.com/ (last visited Mar. 30, 2005). In January 2003, Hyseq, Inc. and Variagenics,
Inc. (U.S.) merged, and changed their name to Nuvelo, Inc. (U. S.). Nuvelo Company Overview,
at http://www.nuvelo.com/about/index.html (last visited Mar. 30, 2005); Millennium
Pharmaceuticals Web Site, at http://www.mlnm.com/ (last visited Mar. 30, 2005).
322. See supratext accompanying note 321.
323. See NuFFiELD COUNCIL ON BIOETHICS, supra note 7, at 50.
324. Id.
325. JAFFE& LERNER, supra note 201, at 203.
326. World Health Organization, Genomics and World Health: Navigating the Information
Jungle- From DNA Sequence to Human Welfare (powerpoint presentation), at http://www.who.
int/ethics/topics/en/cook-deegan-Jul04.pdf (last visited Mar. 30, 2005).
327. ALBRIGHT, supra note 5, at 24-25.
328. Id. at 25.
329. Id.
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to talk about it."33 This is not so anymore, and geneticists are wondering
if "the attitude of withholding data is eroding the scientific method in
genetic research."33 '
Furthermore, there is the problem of the anticommons for
biotechnology.33 2 Renowned organizations, composed of leading scientists
engaged in genome research, scientific advisors to biotechnology
companies engaged in genome research, and representatives from
government agencies involved in genome research, oppose the patenting
of partial and uncharacterized DNA sequences for this reason.3 33 Dr.
Abdallah Daar, an ethicist at the University of Toronto who commented
on Utah-based Myriad Genetics' threat to sue Canadian provinces if they
used breast cancer genes (BRCA1 and BRCA2) to screen patients, said
Myriad was like an inventor of a mousetrap that claims he owns any
device that traps mice.334 Daar says, "'Nobody can own our genes. They
are property of us human beings."'335 Groups like the Canadian Cancer
Society (CCS) fear that "as more genetic therapies come into use, genepatent owners may stop others from making new, possibly better tests. '336
CCS president Julie White says gene-patenting "'really puts a chilling
effect on research.' 337 However, BioteCanada, claiming to represent 85%
of all Canadian genetic researchers, defends gene patents, saying patents
balance the risk and high costs of genetic research with the hope of
financial returns.338
C. The Grantingof EST PatentsHas Already CreatedLitigation
Because of Upstream Clogging
Though the motivating concern behind complaints is the anticommons
problem, and its dampening effect on vital therapeutic or curative research,
there is also the high cost of litigation. The early twentieth century gives
a predictive example of patent infringement litigation over patented natural
substances.

330. Id. at 25-26 (citing Jennifer C. Christiansen, The Price of Silence, Sci. AM., Nov. 1996
(quoting biologist Derry Roopenian at Jackson Laboratory)).
331. Id.at25.
332. See Heller & Eisenberg, supra note 265, at 698.
333. See HUGO Statement, supra note 83.
334. Ken Ernhofer, Ownership of Genes at Stake in Potential Lawsuit, CHRISTIAN SCI.
MONITOR, Feb. 27, 2003.
335. Id. (quoting Dr. Abdallah Daar).
336. Id.
337. Id. (quoting Julie White).
338. Id.
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In Parke-Davis & Co. v. H.K Mulford Co., a "purified" form of
adrenaline was patented, and litigated by a subsequent inventor who found
a different process for obtaining a less purified adrenaline.339 Recognizing
that one patent was a product patent for a composition of matter
("purified" adrenaline), and the other for a different process that produced
less pure adrenaline, Judge Learned Hand concluded that, "considering the
similarity of the processes, the use of each substance practically, and the
approximation of result physiologically, the two are near enough to be an
infringement one of the other."34 It appears gene fragment patents will,
likewise, have to "duke it out" in court.
34
A recent example involves what scientists have called "junk DNA,- 1
which is apparently not junk, and for use of which biotechnology
companies are now being sued.342 Since it was considered junk DNA,
which had no function, it is really ironic that someone actually obtained a
patent on it.343 The happy owner of the "junk DNA" patents is Genetic
Technologies Limited (GTL), and it claims to have a "strong intellectual
property portfolio" that includes two key DNA-related patents: the first on
"DNA analysis, covering non-coding regions of DNA from any species"
(misleadingly known until recently as 'junk DNA') and the second on a
method for gene mapping. 344 Because the "coding" regions of DNA take
up only two percent of DNA,345 it is reported that GTL owns 95% of the
DNA in humans, plants, and animals, and that these patents were awarded
before anyone had really found a specific function for the DNA.346

339. See Parke-Davis & Co. v. H.K. Mulford & Co., 189 F. 95,97-98 (S.D.N.Y 1911), affd,
196 F. 496 (2d Cir. 1912).
340. Id. at 99.
341. E.g., GONICK & WHEELIs, supra note 6, at 147; see also Wong et al., supra note 36;
ALBERTS ET AL., supra note 48, pt. IV, § 14; EuGENE V. KOoNiN & MICHAEL Y. GALPERIN,
SEQUENCE-EVOLUtnoN-FUCnTON: COMPUTATiONAL APPROACHES iN CoMNARATiVE GENoMIcs
§ 9.2 (2003).
342. See ALBRIGHT, supra note 5, at 27.
343. GeneType AG (CH) is the assignee of the "junk DNA" patents, but its parent company
is an Australian company called Genetic Technologies Limited, which owns eleven companies
located in Australia, Switzerland, Canada, and the USA. See Biotechnology Directory, Business
and Research Organisation Contact and Links Directory [hereinafter Biotechnology Directory], at
http://www.biotechnology.vic.gov.au/directory/search-results.asp?id=5261 (last visited Mar. 30,
2005). The local company is called GeneType Corp., and it owns U.S. Patent Nos. 5,612,179 ('179)
(issued Mar. 18, 1997); 5,851,762 ('762) (issued Dec. 22, 1998); and 5,192,659 ('659). Patent' 179
was a C-I-P of '659 (issued Mar. 9, 1993). See United States Patent and Trademark Office Web Site
[hereinafter Patent Office Web Site], at http://www.uspto.gov (last visited Mar. 30, 2005).
344. Biotechnology directory, supra note 343.
345. Genomics, supra note 25.
346. ALBRIGHT, supra note 5, epilogue.
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Nevertheless, GTL guards their patents zealously. In July 2003, Dr.
Francis Collins, the director of the National Human Genome Research
Institute (NHGRI) at the National Institutes of Health (NIH), interrupted
his keynote speech at the International Congress of Genetics in Melbourne,
Australia, in order to publicly rebuke GTL. 347 Dr. Collins charged the firm
with hijacking drug research with "flimsy patents" covering huge strips of
so-called junk DNA, which are "biological bits" once thought
insignificant, but are now central to the work of disease hunters.348
But it gets worse, because now this "junk DNA" plays a crucial role in
telling genes when to express, and when not to express.349 Scientists are
now shocked when they discover that an obscure company actually has a
patent on the "junk. 350 Unfortunately, many are finding out upon receipt
of cease and desist letters or lawsuits. Dr. Mervy Jacobson, GTL's
chairman, has compiled a list of more than 1,800 companies whose work
he thinks infringe GTL's patents, and he says "[t]he world has become our
research lab.'
In about 14 months, GTL, whose gross revenues were $3
million the year before, has taken in $7 million for licensing fees alone; if
you do not pay, GTL will sue you." 2 In October 2003, three U.S. firms
faced infringement suits for refusing to pay licensing fees. 35 3 One of the
threatened companies, Applera, was using the non-coding DNA for cystic
fibrosis diagnostic tests.354 GTL is also demanding $1,000 for academic
licenses, and $5.7 million in licensing fees from the New Zealand
Department of Health. 3 "
D. The Grantingof EST PatentsHas Been Done When the EST's Use
Was Unknown
There is also the problem of "owning a gene you know nothing
about." 356 "'It's like patenting an airplane that doesn't have a tail. They

347. Zina Moukheiber, Junkyard Dogs, FORBES.COM, Oct. 6, 2003, at http://www.forbes.
com/global/2003/1006/022.html (last visited Mar. 30, 2005).
348. Id.
349. See id.
350. Id.
351. Id.
352. Moukheiber, supra note 347.
353. Id.
354. Id.
355. Id.
356. ALBRIGHT, supra note 5, at 26.
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know it won't fly, but they'll stop everyone who has an airplane with a
tail.'357

Commenting on its patented CCR5 gene, which subsequent to
patenting was discovered to have potentially lifesaving use for HIV/AIDS
patients, the CEO of Human Genome Sciences (HGS), William Haseltine,
told the Los Angeles Times: "'If someone uses [the CCR5] gene in a
discovery program. . . and does it for commercial purposes, they have
infringed the patent.' . . . 'We'd be entitled not just to damages, but to

double and triple damages. ,'35 Within eight months of Mr. Haseltine's
threat, HGS's stock rose 111%.359 But the CCR5 gene was one of hundreds
submitted to the PTO by HGS while it did mass-sequencing of the human
genome, and when it applied for the patent, HGS had no clue that CCR5
had any connection to AIDS, or that it was possibly the first step toward
developing a cellular "block" against AIDS.36 ° In fact, the patent
application for the CCR5 gene claimed its utility "could be a receptor for
a virus (a claim that could be made for any cell surface molecule)."36 '
Furthermore, soon after the PTO awarded the patent, serious mistakes
were found in the original patent application, and it was also discovered
that HGS incorrectly mapped the gene.362 Yet now all research and
possible new drugs that might be developed to block the HIV viruses'
entry into a cell will be controlled by one corporation. 363Unless challenged
in court, HGS retains the patent.3 "
Furthermore, a review of patents issued on ESTs is disheartening. For
example, U.S. Patent 5,817,479 ('479) was granted to Incyte in 1998 for
human kinase homologues that were based on 12 EST sequences claimed
to predict the function of the genes from which the ESTs were derived.365
The '479 patent states that the nucleotide sequences may be used in
molecular biology techniques that have not yet been developed, to
357. Id.(quoting John P. Moore, Aaron Diamond AIDS Research Center, commenting on the
CCR5 patent by Human Genome Sciences).
358. Id.at 27 (quoting Paul Jacobs & Peter G. Gosslin, Robber Barons of the Genetic Age:
Experts Fret Over Effect of Gene Patents of Research, L.A. TIMES, Feb. 28, 2000;
BLOOMBERG.COM FINANCIAL MARKETCOMMODITIESNEWS, retrieved from Company Graphs, Oct.
26, 2000).
359. Id.at 27.
360. Id.
361. ALBRIGHT, supra note 5, at 28 (quoting Letter from National Advisory Council for
Human Genome Research, National Institutes of Health, to Commissioner of Patents and
Trademarks, Mar. 21, 2000).
362. Id. at 28-29.
363. Id.at 27.
364. Id.at 29.
365. NumLnD CouNCaL ON BIOETHICS, supra note 7, at 33 n.27.
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generate probes for mapping the native genomic sequence, to design
oligonucleotide primers for the extension of the cDNAs to full length, and
to produce a kinase kit for diagnosing disorders or diseases associated with
altered kinase expression. 66 This seems to directly contravene even the
CAFC's most liberal opinion. Something must be done.
X. PROPOSALS

Human genes are special. Genes are our common heritage.367 Perhaps
one extreme remedy would be to approach DNA fragment patents as Louis
Pasteur approached his novel discoveries, obtaining patents on substances
like yeast (which now would likely not be allowed).368 He placed them in
the public domain.369 But because of the profit motive, this could never
happen today.370 However, the current state of affairs in genomic patenting
must be fully elucidated and the consequences addressed. The
recommendations proposed below are not final solutions. To find the
appropriate solution would require cooperation between organizations on
both sides of the fences (i.e., not-for-profit research versus for-profit
research). However, the ideas proposed below contain elements that
should provoke discussion and action by those who are in a position to
reverse the inertia of doing nothing.
A. Use Patents
Because little, or nothing, of a chemical nature would be found lacking
in utility,37 ' not every use asserted can be sufficient to satisfy section 10 1
and 112 of title 35 of the U.S. Code. Indeed, since the outset,
commentators have argued potential patentees should be forced to commit
to uses for the ESTs, and EST-related products, in the specification and
claims of patent applications.372 If not, when other researchers discover
other critical uses for the genes and their products, they will not be able to
366. See U.S. Patent No. 5,817,479 (issued Oct. 6, 1998).
367. See NUFFIELD COUNCIL ON BIOETHICS, supra note 7, at 21 ("It is argued that the human
genome is unique and distinctive, so it should be treated differently from others such as the
genomes of mice or maize, for example.").
368. MERGES & DUFFY, supra note 17, at 95.
369. Id.
370. See generally ALBRIGHT, supra note 5; SHREEVE, supra note 90.
371.

See Brenner v. Manson, 383 U.S. 519, 530 (1966).

372. Joseph P. Pieroni, The Patentabilityof Expressed Sequence Tags, 9 FED. CIR. B.J. 401,
412 (2000).
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patent those uses without conflict, as already seen with the HGS CCR5
gene and the GTL "junk DNA" patents.
The Nuffield Council on Bioethics identifies three different types of
patents: (1) product patents; (2) process patents; and (3) use patents.3 73 A
"use" patent is a patent on the use of the patented invention for a specific
purpose, and only the specified use is covered. 374 Because of the
degeneracy of the genetic code, one way to avoid the negative effect of
composition of matter patents on DNA sequence patents is to limit the
patent rights granted on DNA sequence claims to only use patents, which
do 7not
assert rights over the DNA sequence itself or all unknown uses of
5
3

it.

Allowing only patents on use is historically valid. Since the early
nineteenth century, the U.S. Supreme Court has reiterated the need for a
use or utility before granting a patent. According to Judge Story, "the
original elementary principles of motion, which philosophy and science
have discovered" is not patentable; but "the modus operandi, the peculiar
device or manner of producing any given effect" is patentable.376
Historically, cases of patentability have turned less on the patentability of
the metaphysical definitions and distinctions about principles and laws of
nature, and more on the fit between the inventor's claims and his inventive
contribution to the subject.377 In the nineteenth century, the patentability
of natural principles was mainly concerned with ensuring "(1) that the
inventor specified a practical utility, and (2) that the patent bore some
relation to the inventor's contribution to the useful arts.

3 7'

"The mere

discovery of a new element, or law, or principle of nature, without any
valuable application of it to the arts, is not the subject of a patent. 379 The
discoverer of a new rule or force of nature could not obtain a patent unless,
and until, he also identified a useful end. 3 " Though an appreciation of all
uses is not necessarily implied or required under current law, it makes
373. NUFFIELD COUNCIL ON BiOETHICS, supranote 7, at 24. Using a pharmaceutical product

as an example, a product patent would cover the active ingredient or a particular formulation; and
process patents would cover the making of the active ingredient or particular formulation. Id.
374. Id.
375. Id. at 53, 66.
376. MERGES & DuFFY, supra note 17, at 96 (citing Whittemore v. Cutter, 29 F. Cas. 1123,
1124 (C.C.D. Mass. 1813) (Story, J.); Barrett v. Hall, 2 F. Cas. 914, 923 (C.C.D. Mass. 1818)
(endorsing Story's view)).
377. Id.
378. Id.
379. O'Reilly v. Morse, 56 U.S. (15 How.) 62, 132 (1853) (Grier, J., dissenting in part).
380. MERGES & DUFFY, supra note 17, at 95 (citing I WILLIAM C. ROBINSON, THE LAW OF
PATENTS § 136, 195-96 (1890); GEORGE TICKNOR CURTIs, A TREATISE ON THE LAW OF PATENTS
§ 136, 149 (4th ed. 1873)).
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sense in the realm of ESTs, since the genetic code contains more value in
it than any other "chemical composition" known to man, in terms of
universal public health, and since so little is currently known about this
supremely complex tool.
Pragmatic inquiries governed then, and they should govern now.
Research will not come to a stand still. As the Supreme Court pointed out
many years ago,
[t]he grant or denial of patents on micro-organisms is not likely to
put an end to genetic research or to its attendant risks. The large
amount of research that has already occurred when no researcher
had sure knowledge that patent protection would be available
suggests that legislative or judicial fiat as to patentability will not
deter the scientific mind from probing into the unknown any more
than Canute could command the tides.38 '
Limiting the patent applicant's monopoly on the specifically identified use
set out in the application would quickly solve any new patents that are
issued. As set out above, DNA patents cannot be treated the same as
chemical composition patents since chemical compositions that do not use
genetic information are generally based on how the body reacts, whereas
DNA patents are based on the code that dictates how the body will
function.
B. "Gene" PatentsIssued Only When Utility Disclosed is in Currently
Accessible andDeliverable Form
Another option would be'to modify the current definition of utility. In
the new definition, the standard of credibility required for a claimed utility
of a DNA sequence would need to be set higher than the mere theoretical
possibility of this utility.8 2 Some positive evidence showing the DNA
sequence has the claimed utility should be required, and the utility should
be more than just a biological function.38 3 Biological functions are only a
description of a fact of nature and are not a practical utility in the usual
sense applied to invented products.3 '"
Congress should define as useful an invention that has "' substantial and
specific utility that is in currently deliverable form.""'38 This would, in
381.
382.
383.
384.

Diamond v. Chakrabarty, 447 U.S. 303, 317 (1980).
NUFFIELD COUNCIL ON BIOETHICS, supra note 7, at 70.
Id.
Id.

385. Daniel L. McKay, Comment, Patent Law and Human Genome Research at the
Crossroads:The Needfor CongressionalAction, 10 SANTA CLARA COMPUTER & HIGH TECH. L.J.
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essence, be a codification of the Brenner standard, and would solve the
problem of companies obtaining patents on gene fragments for which they
know no function or utility.386 Researchers have been apprehensive
because the breadth of claims granted on mere fragments of a gene would
prevent them from gaining protection for the entire gene when the
complete structure was discovered.3"7 In addition, a very broad claim
might cover the actual protein coded for by that gene, again based on very
little of the gene itself.3"8 This would prevent patent owners from later
claiming uses not currently available or deliverable, and it would leave
open to others the option of obtaining a patent on a later discovered use.
Of course, some system would need to be put in place on the matter of
whether a subsequent researcher or inventor would be required to pay
licensing fees on the same EST before she discovers the new use. As a
result, the best combination would be to make the definition of utility more
strict, then combine this with a use patent limiting the patent owner's
rights, and right to demand payment, to only uses of the EST that are the
same or sufficiently similar, under the doctrine of equivalents.
C. "Gene" Patents Issued Only When Beneficial Utility or Use
Requirement Met
Because the most critical problem with EST patents is their prohibitive
effect on research that is in the best interests of public health, the concept
of beneficial utility may be perfectly suited to limiting the scope of patents
granted for ESTs. In addition, the story of filing the chimera (sometimes
called the huMouse) patent application must be told, since this horror story
succinctly describes the slippery slope that can result from granting any
type of gene patents.
Dr. Stuart Newman and Jeremy Rifkin jointly filed an application for
animal-human hybrids named "chimeras,"389 and for the process of making
these creatures.3 90 The patent application disclosed creatures that melded
human and animal embryos such as "the huMouse, a mixture of man and
mouse; the humanzee, a cross between a human and chimpanzee; and
blends of human with pig and human with baboon."3 9 ' Disclosed uses were
465, 495 (1994) (quoting Thomas Kiley, Patentson Random Complementary DNA Fragments?,
257 SCIENCE 915, 920 (1992)).
386. See id.
387. Pieroni, supra note 372, at 411.
388. Id.
389. The name "chimeras" is from the mythical Greek monster with a goat's body, a lion's
head, and a serpent's tail. Slater, supra note 123.
390. MERGES & DuFFY, supra note 17, at 225.
391. Slater, supra note 123.
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to study embryonic development, raise organs for transplants, or test new
drugs.3 92 This patent application clearly identified the problems associated
with the fact that under the laws currently in place, and the PTO's policy
that it does not engage in ethical or moral evaluations of patent
applications, this application could have been granted. In indirectly
addressing this application, the Commissioner of the PTO made the
following statement:
No patent is granted for an invention that does not meet the strict
patentability requirements set forth in patent laws contained in title
35 of the United States Code. These include requirements that the
invention have utility, be novel and non-obvious, and be adequately
described and disclosed so as to enable the making and using of the
invention. The PTO will not, therefore, issue a patent for an
invention of incredible or specious utility or for inventions whose
utilization is not adequately disclosed in the application.
Additionally, the courts have interpreted the utility requirement to
exclude inventions deemed to be "injurious to the well being, good
policy, or good morals of society."39' 3

In directly addressing the chimera patent application, the PTO
Commissioner stated, "[T]here will be no patent on monsters, at least not
'
What is most frightening about the
while I'm commissioner."394
Commissioner's statement is that he could not cite to any portion of the
patent statute as grounds for rejecting the patent application. The
Commissioner had to cite to a case from 1817 that had been quoted by a
case in 1991. Furthermore, the PTO never raised the utility requirement,
since it merely rejected the application on grounds that human hybrid
creatures were not patentable subject matter, without further comment.39 5
It must be noted, too, that Newman's and Rifkin's purpose for filing the
chimera patent application was to prevent anyone else from filing such an
application.3 96 Indeed, Newman is both a developmental biologist and a
founding member of the Council for Responsible Genetics, a
392. Id.
393. Media Advisory, U.S. Patent and Trademark Office, Apr. 1, 1998 (quoting Lowell v.
Lewis, 15 F. Cas. 1018, 1019 (C.C.D. Mass. 1817) (No. 8,568)), available at http://www.uspto.
gov/web/offices/com/speeches/98-06.htm (last visited Mar. 30, 2005).
394. MERGES& DUFFY,supra note 17, at 225 (citing "Morality"Aspect ofUtility Requirement
Can Bar Patentfor Part-HumanInventions, 55 PAT. TRADEMARK & COPYRIGHT J. (BNA) 555
(1998)).
395. Id.
396. See Slater, supra note 123.
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biotechnology watchdog group. a97 Both applicants reasoned that, if they
obtained the patent they could "lock up" any subsequent attempts to patent
chimeras, but if the patent was rejected the PTO could use the rejection to
block other similar applications.3 98
If modified to require beneficial utility, the patent applications on
genetic information could be tested in a way that would protect public
health and, incidentally, also fall in line with articles 8 and 27 of TRIPs.
Then-Judge Story interpreted the word "useful" to mean, generally,
beneficial to the public, in the sense that it would not, inter alia,injure the
"well-being, good policy or sound morals of society. ' , He also explained
that an invention that would poison people would not be useful; but in his
interpretation, anything not hurtful would likely be patentable even if not
"extensively useful," since the market could deal with this lack of utility.4"
Interestingly, as applied to inventions in the early nineteenth century,
Story's view of utility was quite liberal. However, as applied to DNA
sequence fragments, it is strict. If a patent application on an EST could
cause blockages or unreasonable increases in the cost of lifesaving
therapies to a price out-of-reach of the average human, the application
would be injurious to the well-being, good policy and sound morals of
society. As a result, the application should be rejected or tailored to
prevent a violation of beneficial utility. Requiring a beneficial utility
would greatly minimize the danger of any patents like Newman's from
issuing. It would also deal with the issuance of patents that would cause
public health, anticommons, and undeserved monopoly problems.
D. Compulsory Licensing of EST Patents
Though it may seem silly at first glance, perhaps EST patents should
be treated like computer code, and placed in a single searchable database,
like music. The genetic code, after all, is referred to and identified by letter
and three-letter codons. In addition, according to Venter, who sequenced
the human genome by using ESTs and automated computers, his company

397. The story begins with a phone call, over ten years ago, from Jeremy Rifkin, who asked
Dr. Stuart Newman if he could design a genetically engineered invention that was technically
feasible, scientifically useful, and yet "so disturbing that it would draw the public's attention to the
possibilities of genetically engineering humans." Slater, supra note 123. After several years of
work, in December 1997, Newman and Rifkin jointly submitted their application to the patent
office. Id.
398. See id.
399. Lowell v. Lewis, 15 F. Cas. 1018, 1019 (C.C.D. Mass. 1817) (No. 8,568).
400. See id.
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was "not a biotech," '' but in fact, something closer to an information
technology company. In August of 1998, Venter said,
[Celera is] an information company, like LexisNexis. If you had the
time, you could find the same information they have on your own.
So why do they have two million subscribers? Because they've
already done the legwork for you, so you can find what you want in
seconds rather than hours. We're going to do the same for genomic
information, on a global scale.4 °2
At that same time, Venter also maintained "'I am not the Bill Gates of the
genome.' . . . 'At least not yet."' 40 3 Though a little boastful, Venter's
statements reveal the nature of the genetic code, as at its core, being pure
information. It is information used by the bodies of humans, animals, and
plants to live.
The problem with allowing patents on this information, as opposed to
copyrights, is that the code can be used for so many different things. In
other words, the uses for each EST can be myriad. As a result,
infringements occur, research is stopped and lawsuits get filed. A system
modeled on the compulsory licensing provision of the Copyright Ac 4 '
may provide a way for tracking who owns a particular EST, and allowing
a for-profit or not-for-profit researcher to pay a fee for use of the EST.
Like the compulsory licensing statute of the Copyright Act, an EST
compulsory licensing system could define the rights held by the owner of
the EST and the limited rights to which the EST licensee would be
entitled. A notice provision to the owner could be included, with penalties
provided for the failure to notify. A royalty provision could contain initial
royalties for nonprofit research uses, and a subsequent, more remunerative
royalty for any composition or process that generates income from the use
of the patented EST. The non-profit research royalty could be designated
by length of time used, and could be nominal. The subsequent royalty for
compositions or processes that generate income could be based on a
percentage of the profit made from composition or process. The
compulsory licensing scheme of the Copyright Act could be the starting
point for a method of dealing with the difficulty of finding out if a
particular patent has issued on an EST, who to contact to get permission
to use the EST, and how to fairly license the EST.

401.
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XI. CONCLUSION

Patents have issued on ESTs. Problems are surfacing because of the
EST patents. The Courts have taken a liberal view, and the PTO has been
overwhelmed. In addition, because of the nature of the patent system, the
complete consequences of granting patents on ESTs will take time to fully
develop. However, as described in this Article, examples of those
repercussions are beginning to surface; EST patents are having a
detrimental effect on public health and are creating litigation for the
Courts. The question, then, is whether EST applications are still pending
at the PTO for which some remedy could be created by Congress. Because
of the difficulty and complexity, described above, of searching issued
patents, and the inability of third parties to review pending patent
applications, a congressional inquiry is needed to determine if there are
any remaining applications on which changes in the law might have an
impact. If there are pending applications, then Congress should consider
changing the definition of utility to include a requirement that either the
invention or discovery and its use be beneficial. Alternatively, Congress
should limit patents on those ESTs to only the uses identified by the
applicant and uses in currently deliverable form at the time the application
is filed. If all applications on ESTs are out of the reach of Congress, then
a compulsory licensing scheme could minimize the problems these patents
have created in limiting research and increasing litigation by fairly
licensing them to those who want to provide beneficial inventions to the
public.

